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Abstract 
 
IMPACT OF E-CIGARETTES ON PHYSICIAN RECOMMENDATIONS OF TOBACCO 
USE CESSATION PHARMACOTHERAPY 
By Omar El Shahawy, MBBCh, MPH 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2015. 
Major Director: Jennifer Elston Lafata, Ph.D. 
Professor, Department of Social and Behavioral Health 
 
 
Introduction: E-cigarettes have been marketed as smoking cessation aids and harm reduction 
strategies. Prior regional surveys found that physicians are recommending them to patients 
despite the lack of evidence supporting these industry claims. Yet, little is known about 
physicians’ beliefs regarding e-cigarettes and whether these beliefs are associated with them 
recommending e-cigarette use in clinical practice. Methods: This three-manuscript dissertation 
used a mixed-methods approach including both qualitative and quantitative research methods. 
The aims were to: (1) Uncover the factors associated with primary care physicians’ (PCPs) 
decisions to recommend e-cigarettes to their patients for tobacco use cessation; (2) Estimate the 
prevalence of PCPs who recommend e-cigarettes to their patients as a tobacco use cessation aid; 
(3) Estimate the influence of factors identified in Aim 1 on PCPs’ decisions to recommend e-
cigarettes to their patients for tobacco use cessation; (4) Evaluate the conceptual model which 
demonstrates the factors contributing to PCPs’ decisions to recommend e-cigarettes to their 
patients for tobacco use cessation. Results: Study 1 found that PCPs expressed a lack of 
information about e-cigarette safety and efficacy along with skepticism about the role of e-
cigarettes in tobacco control in general and in smoking cessation in particular. However, once a 
 
 
   
patient initiates a discussion with them, PCPs seem to be endorsing patients’ interests in using e-
cigarettes, as well as recommending e-cigarettes to particular types of patients who smoke for 
both smoking cessation and as a harm reduction strategy. Study 2 found that over three-quarters 
(82.7%, n=220) of PCPs reported previously discussing e-cigarettes with their patients. Overall, 
57.8% (n=155) reported previously recommending e-cigarettes to an adult patient who smoked.  
Among those recommending e-cigarettes, the majority reported recommending them for 
smoking cessation and harm reduction (71.6%, n=111), 18.8% for smoking cessation only, and 
9.6% for harm reduction only. The likelihood of recommending e-cigarettes to patients was 
associated with considering their patients’ interest in using e-cigarettes, PCP’s belief that e-
cigarettes can help in quitting smoking, and PCP’s belief that e-cigarettes limit secondhand 
smoke exposure for others. Study 3 found that PCPs intend to recommend e-cigarettes for 
smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1), followed by heavy smokers 
wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit (mean=3.50, ±2.2). The mean 
for PCPs’ recommendation intentions was 3.04 (±2.0) for light smokers wanting to quit, and 3.01 
(±1.9) for light smokers refusing to quit. Nevertheless, these recommendation intentions were 
driven by PCPs’ beliefs and perceptions of e-cigarette benefit and harm; however, these 
intentions varied by patients’ tobacco use profile. Discussion: Findings across the three studies 
highlight the significance of PCPs’ beliefs in driving their recommendations of e-cigarettes 
versus evidence based knowledge, as well as, the importance of patients’ factors and interest in 
using e-cigarettes for PCPs’ recommendations for e-cigarette use.
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Chapter 1: Introduction 
 
Tremendous strides have been made in the United States (US) to control tobacco-related 
morbidity and mortality.1 Nonetheless, a wide range of new and emerging tobacco products (See 
Table 1), are thriving that may threaten these achievements .2 These products are being mostly 
marketed as “alternative” products to conventional cigarettes that are well known by the US 
public to be very harmful.2-4 Some of these products burn or heat tobacco (i.e. combustible) and 
others are non-combustible products; both promise to reduce or eliminate the associated risk of 
conventional cigarettes and can subsequently mislead US consumers to believe that safe tobacco 
or nicotine use is currently possible.5  
Table 1:  Descriptions of Different Classes of New and Emerging Tobacco Products 
o Chewing tobacco - Any leaf tobacco that is not intended to be smoked.  
o Cigars - Any roll of tobacco wrapped in tobacco leaves or in any substance containing tobacco 
(other than any roll of tobacco which is a cigarette).  
o Dissolvable Tobacco (known as “hard snuff”) – A tobacco product made from tobacco that 
dissolves away in your mouth and provides the same tobacco satisfaction as cigarettes or 
smokeless tobacco.  
o Electronic Nicotine Delivery Device ( known as “Electronic Cigarette”)– A unit comprised of a 
battery, an atomizer, and a cartridge that contains a liquid to be vaporized which is inhaled and 
exhaled, mimicking the action of smoking. The liquid often contains nicotine.  
o Hookah/Waterpipe – Although known by many different names (e.g., hookah, narghile, shisha), 
the term waterpipe has been used for the last two decades in the English language scientific 
literature to refer to any of a variety of instruments that involve passing tobacco smoke through 
water before inhalation.  
o Snuff - Any finely cut, ground, or powdered tobacco that is not intended to be smoked.  
o Snus - A moist powder tobacco product originated from a variant of dry snuff, in the early 19th 
century in Sweden, consumed by placing it under the lip for extended periods of time. Snus is a 
form of snuff that is used in a manner similar to American dipping tobacco, but typically does not 
result in the need for spitting. Snus is also unique in that it is steam-cured rather than fire-cured, is 
not fermented and contains no added sugar.  
Adapted: Barry et al, 2010 
The current study focuses on the most recently introduced product in 2007,6 which is 
rather a class of products called electronic nicotine delivery devices or e-cigarettes, which share 
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some common features.7, 8 These features include being battery-powered, converting nicotine-
containing liquid into a vapor that can be inhaled, and producing white vapor upon exhalation 
(called vaping). Some e-cigarettes further mimic the conventional cigarette by having an LED 
that illuminates during use.7, 9 Due to a lack of marketing restrictions and the availability of e-
cigarette producers, including major tobacco companies, e-cigarettes have evolved rapidly to 
become one of the fastest growing classes of nicotine containing products in the US. 10 In fact, 
the sales of e-cigarettes are projected to surpass that of conventional cigarettes by the year 
2021.11 Further, the first generation e-cigarettes were not efficient in delivering nicotine.12 Since 
the nicotine yield of e-cigarettes varies by design, e-cigarette nicotine concentration and other 
technical features, e-cigarettes have currently progressed to their third generation (called e-mods) 
undergoing a series of changes in all the aforementioned technical features. As such, they have 
become much more efficient in delivering nicotine than conventional cigarettes.8, 12-14 
As evidenced by a number of research studies, e-cigarette experimentation, use, and 
promotion have been growing exponentially over the past few years.6, 15-17 E-cigarette 
advertisements often target tobacco users with the claim that e-cigarettes can facilitate tobacco 
use cessation or provide a way to smoke without restrictions, and they often offer a “free trial” to 
make them more appealing.3 In other words, manufacturers are relentless in their promotion of e-
cigarettes as safe alternative to conventional cigarettes or as a smoking cessation aid.14,15  
Moreover, the e-cigarettes industry has been spending a substantial amount of money on 
advertising 18 that often targets youth and young adults.19 Thus, on the US national level, 
younger individuals generally seem to be more susceptible to e-cigarette use than older 
individuals, irrespective of their smoking status.20-22 In fact, teen use of e-cigarettes surpassed 
that of any other tobacco product in the US in 2014, raising concerns that e-cigarette use could 
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become the new gateway to conventional cigarettes and other tobacco product initiation as well 
as further drug addiction.23 Recent cross-sectional studies have found that former smokers are 
more prone to using e-cigarettes than never-smokers, and current smokers are much more prone 
to using e-cigarettes than both never and former smokers.20-22 A recent US national trend 
assessment showed that e-cigarette use has been exponentially increasing among smokers and 
non-smokers alike over the past few years, with the use of e-cigarettes estimated to have reached 
more than 30% among daily and non-daily smokers in 2013 reflecting an evolving dual use of 
cigarettes and e-cigarettes. 24 Thus, e-cigarette dual use and gateway to other forms of tobacco 
use are two major concerns that have been long discussed among tobacco control researchers and 
have resulted in a concern that e-cigarettes could help renormalize tobacco use.25 
E-cigarettes and Tobacco Control: The Debate over Harm Reduction and Smoking 
Cessation 
E-cigarettes are believed to be safer than conventional cigarettes. This belief is held by 
many26-30 including physicians.31-33 However, e-cigarette vapors are not pure nicotine; they 
contain a complex mixture of potentially lethal chemicals.34, 35 Thus, assessments of the abuse 
potential and long-term adverse events are still needed,9 and the health implications are yet to be 
understood.36 Whether e-cigarettes could be a safe substitute for regular cigarettes is not 
known,37, 38 and pending any regulation by the US Food and Drug Administration (FDA), the 
safety issues associated with the use of currently marketed e-cigarette products in the US is not 
expected to be resolved anytime soon.29 E-cigarettes contain nicotine in varying levels.39 At 
times there is no nicotine,29 and fewer carcinogens than are found in conventional cigarettes.40, 41 
On the other hand, other harmful ingredients have been found in e-cigarettes such as diethylene 
glycol which is a toxicant found in antifreeze.42, 43 Moreover, the main constituent of the e-liquid 
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(propylene glycol) has been rendered safe to use in some FDA-approved injectable drugs but has 
never been tested for inhalation in human lungs. The long- and short-term effects of inhaling 
such products remain unknown.44 Thus, the potential of e-cigarettes to be a viable harm 
reduction strategy by minimizing tobacco use-related morbidity and mortality among those who 
use them is not known and is difficult to project given the unresolved safety concerns.45 
Nevertheless, there are researchers who support the use of e-cigarette for harm reduction,14, 45 
and others who do not support e-cigarette use as a harm reduction strategy as this approach is 
believed to be currently non-evidence based.46  
E-cigarettes, since their emergence in the US market, have been heavily marketed as 
smoking cessation aids.29 An abundance of websites contain testimonials from current and 
former tobacco users as well as endorsements by physicians who, based on experiences with a 
few patients, promote e-cigarettes as effective and safe cessation agents.2, 4, 47 Although e-
cigarettes are not currently regulated by the FDA, some cities in the US have banned use of e-
cigarettes in public places.48 Also, other countries have taken action to control the fast growing 
market of e-cigarettes. The European parliament issued a ban on e-cigarette advertising that is 
scheduled to go into effect in the 28 European union countries in 2016.49 Further, the United 
Kingdom has banned nicotine liquid concentrations higher then 20mg/ml in an attempt to control 
the nicotine yield.50  
Recently, there have been a number of studies aiming at exploring their effectiveness as a 
smoking cessation tool.37, 51-53 However, most of these studies lack a rigorous research design or 
biochemical validation for nicotine abstinence, or they rely on self-reported data from online 
surveys51 which could potentially include favorable biased responses from e-cigarettes 
enthusiasts.54 For example, Polosa et al. (2011) followed 40 smokers who were unwilling to quit 
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but attempting to experiment with e-cigarettes as a method of tobacco reduction and possibly 
cessation. They reported significant decreases in the amount of cigarettes smoked by study 
participants. Bullen et al. (2010) conducted a randomized cross-over trial in New-Zealand among 
40 adult dependent smokers. The e-cigarettes that were used in this study were found to alleviate 
nicotine craving upon overnight abstinence.38 Until 2013, use of e-cigarettes did not correlate 
with successful quit attempts.55 However, there is evidence that smokers try it in an attempt to 
quit,52 and the first clinical trial published in September of 2014 suggested that e-cigarettes could 
be as effective as nicotine patches in helping cigarette smokers quit.56 Finally, a more recent 
cross-sectional study from England, without biochemical validation, surveyed smokers trying to 
quit with e-cigarettes, approved cessation medications, or with no assistance. This study found 
that there was a small, but statistically significant, continued abstinence among e-cigarette 
users.57  
Each of the aforementioned studies concluded that e-cigarettes might have a future in the 
arena of smoking cessation, but acknowledged the need for more rigorously designed research.  
Furthermore, most of these existing studies either did not report financial disclosure or reported 
support by the manufacturers of these products.37, 38, 51, 52 A recent meta-analysis of these existing 
studies supported e-cigarettes as a potentially effective smoking cessation aid.58 Nevertheless, 
the available data regarding e-cigarettes efficacy in smoking cessation is not conclusive and thus, 
e-cigarettes have not been endorsed by any professional health organization as an effective tool 
for smoking cessation, including the American Heart Association,59 the American Association 
for Cancer Research, the American Society of Clinical Oncology,60 or the United States 
Department of Health and Human Services.61 Additionally, the current tobacco use cessation 
guidelines state that the use of any tobacco product should be discontinued; quitting all forms of 
 
 
6 
 
tobacco use is the only known method for decreased morbidity from tobacco.62 There is valid 
concern that smokers would use other forms of tobacco in conjunction with e-cigarettes, creating 
dual users or continue using e-cigarettes exclusively.4, 53 Thus, the prospects of e-cigarette use in 
smoking cessation are still unresolved. 
Physician Tobacco Use Counseling: A Current Perspective 
Many tobacco users are now identified and offered cessation assistance during physician 
office visits.63, 64 Tobacco use cessation discussions with physicians are considered an evidence-
based brief intervention to help tobacco users quit.65, 66 In 1996, the US Public Health Service 
first published evidence-based clinical practice guidelines for treating tobacco use and 
dependence.62, 67 Since that time, recommendations for physicians have remained unchanged.62, 68 
Physicians should ask patients about their tobacco use on every possible occasion  as well as 
counsel current tobacco users using a 5 As approach (ask about tobacco use, advise to quit, 
assess willingness to make a quit attempt, assist in quit attempt, and arrange follow-up).62, 69, 70  
If the patient is not ready to quit, recommendations are for the clinician to divert from the 5 A’s 
approach after the “Assess” step, and instead use brief motivational counseling based on a 5 R’s 
approach (i.e., relevance, risks, rewards, roadblocks, repetition).69 Primary care is an ideal venue 
for the delivery of such interventions,62 as periodic health exams are regarded as a time for 
preventive health-related counseling by physicians on tobacco use among other issues.71 A 
physician’s visit serves as a trigger for tobacco use quit attempts.72 Further, tobacco users 
perceive a physician's advice to quit as a strong motivator for a cessation attempt.73-75 A 
Cochrane review concluded that brief advice by physicians versus no advice significantly 
increases quit rates,76 and this brief advice is deemed as the standard of care for tobacco use 
cessation counselling.62 
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The emergence of e-cigarettes is believed to be interacting with physician cessation 
counseling behavior.77 There is no identified published literature detailing physicians’ counseling 
practices regarding e-cigarettes either inside or outside the US; however, there is anecdotal 
evidence that US physicians recommend e-cigarettes for tobacco use cessation based on their 
personal experiences and information obtained from their colleagues.78 Such anecdotal 
information is beginning to be confirmed via large scale research efforts. For example, a recent 
survey of practicing physicians in North Carolina found that discussing e-cigarettes with patients 
was not an uncommon practice albeit being patient initiated.32 Another online survey yielded 
similar conclusions using a quota sample of physicians practicing in different specialties.33 
Discussing smoking cessation recommendations with the advent of e-cigarettes, in light of 
inconclusive evidence regarding their safety and efficacy in cessation,59-61 is likely to cause 
additional complexities for clinicians,77 particularly among primary care physicians (PCPs) who 
currently deliver the vast majority of office-based physician tobacco cessation counseling63, 64, 79 
and are at the forefront of the US health care system. Despite guideline recommendations to do 
so,62 even before the emergence of e-cigarettes, clinicians counseling current tobacco users have 
not always recommended FDA-approved cessation pharmacotherapy.80 Some physicians have 
negative attitudes toward providing pharmacotherapy for cessation,81 and these perceptions 
greatly moderate prescribing behavior.82 A study by Bhatia et al (2006) found that there are four 
main drivers of physician pharmacotherapy choice: product characteristics; promotional 
activities; patient treatment history and co-morbidity; and price-related issues.83 E-cigarettes are 
rapidly evolving with regard to the product characteristics with varying price categories and 
there is limited knowledge about their safety and efficacy for smoking cessation,29 but PCPs are 
likely lacking information about these aforementioned topics.31, 32 Additionally, promotional 
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activities (a third driver) are abundant and currently unregulated, centering on the message that 
e-cigarettes are a safe alternative and can help in quitting.3, 47 Such activities could be  affecting 
PCPs beliefs and knowledge regarding e-cigarettes as some of them reported that they gather 
their information from their patients, the lay-press, and e-cigarette advertisements.31 In summary, 
e-cigarettes represent a new product that could be challenging the use of FDA-approved 
pharmacotherapy cessation aids or more broadly altering the dynamics of smoking cessation 
counselling. E-cigarettes are likely a “hot topic” for discussion during physician office visits and 
their emergence could be forcing physicians to give an opinion on them once a tobacco use 
cessation discussion takes place, despite the lack of empirical evidence regarding the benefit of 
these products in smoking cessation. 
Current Knowledge about Physicians’ E-cigarettes Recommendations 
Despite the ever growing access among the US public to medical information, the 
preference of the majority (70%) continues to be obtaining health information from their 
physicians. 84 Moreover, physicians remain the most trusted source of health information.84, 85 In 
the absence of a clear set of recommendations from clinical practice organizations or regulatory 
actions from the FDA,86 PCPs likely face a challenge when addressing patient inquiries 
regarding e-cigarettes. Understanding the burden on PCPs in providing tobacco counselling-
related information is of critical importance as there are an abundance of opposing views and 
conflicting evidence regarding e-cigarette safety and benefits with no conclusive guidance in 
clinical practice.37, 38 For example, the American Heart Association issued its first set of policy 
recommendations regarding e-cigarettes including counselling recommendations to physicians 
using the existing body of literature at the time.59 They recommended that physicians screen for 
e-cigarette use. However, they acknowledged that there was no evidence to support e-cigarette 
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use or recommendation for cessation. On the other hand, there was also no evidence to support 
deterring patients who had previously tried other cessation aids unsuccessfully and were 
interested in using e-cigarettes.59 
Existing surveys of physician attitudes and perceptions in the US confirm that e-
cigarettes are being discussed, and that physician opinions are being solicited by patients, 
especially among primary care specialties.31, 32 Four out of five physicians reported being asked 
about e-cigarettes by their patients who used tobacco in one study and nearly half of physicians 
who believed that e-cigarettes may assist in cessation already had recommended them to their 
patients.32 Physicians who were younger, believed that e-cigarettes lowered the risk of cancer, 
had been asked more often about e-cigarettes by their patients and had a process in place to 
document tobacco treatment counseling were more likely to report making such a 
recommendation. These results were consistent with another survey that found that many 
physicians are being asked about e-cigarettes and are recommending e-cigarette use to their 
patients.33 However, the full range of factors which contribute to physicians attitudes, 
perceptions and decisions to recommend e-cigarettes remains largely unknown.31, 32 Without 
knowledge of the factors that are likely to impact e-cigarette recommendations in clinical 
practice, up-to-date program planning for addressing the current challenges in tobacco use 
counselling in physicians’ offices remains at a standstill. 
The Aims of My Research 
The overarching objective of my dissertation research was to understand the patient, 
physician and other influences pertaining to the adoption of e-cigarettes into a primary care 
physician’s tobacco cessation counseling. Since approximately half of the physician office visits 
in the US are with PCPs,79 and tobacco use is screened in approximately 75% of the visits in 
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primary care,64 I targeted PCPs to evaluate physicians’ behavior. My primary research question 
was centered on understanding how e-cigarettes are being incorporated into primary care tobacco 
use cessation counseling. I also identified the underlying salient factors that contributed to PCP 
endorsement of e-cigarettes when engaging in tobacco use cessation counseling. My exploration 
of how physicians and patients discuss e-cigarettes in clinical practice, and how these discussions 
affect physicians’ recommendations of their use, requires an in-depth understanding of 
physicians’ perceptions of e-cigarettes. My research was guided by the Theory of Reasoned 
Action (TRA).87, 88 Because the environment surrounding cessation discussions is also important, 
I augmented the TRA with the concept of patient interest for a specific treatment option that is 
highlighted by the Model of Clinical Decision Making (MCDM). TRA suggests that attitudes 
and subjective norms contribute to physicians’ intentions and subsequent decisions to 
recommend e-cigarettes to their patients once the tobacco use cessation discussion takes place.87, 
89, 90 MCDM suggests the patient’s interest in receiving a specific treatment becomes more 
important for physicians if they are addressing a chronic problem that is not immediately life 
threatening to the patient.91 All these domains interrelate which prompted me to combine them in 
a TRA-informed conceptual model. This resulting combined conceptual model guided my 
research as depicted in Figure 1.  
 
 
 
 
 
Figure 1: Model of the Factors Influencing Physicians’ Decision to Endorse E-cigarettes 
Patient Interest 
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My research study was carried out in two phases. Phase-1 used qualitative methods to 
discover the factors associated with PCP recommendation of e-cigarettes for tobacco use 
cessation. This formative research included an elicitation procedure to identify relevant 
behavioral outcomes and referents. To do so, I used semi-structured interviews  in which PCPs 
were asked to provide three types of information: 1) Positive or negative feelings about 
recommending e-cigarettes as a tobacco use cessation aid (experiential attitude or affect), 2) 
Positive or negative attributes or outcomes of recommending e-cigarettes as a tobacco use 
cessation aid (behavioral beliefs), and 3) Individuals or groups to whom they might listen who 
are in favor of or opposed to the recommendation of e-cigarettes as a tobacco use cessation aid 
(normative referents). Phase-2 used quantitative methods to estimate, among others variables, 
the prevalence of e-cigarette recommendation for tobacco use cessation and its related factors. In 
so doing, my research was designed to address the following aims:  
Aim 1: Uncover the factors associated with PCPs’ decisions to recommend e-cigarettes to 
their patients; 
Aim 2: Estimate the prevalence of PCPs who recommend e-cigarettes to their patients; 
Aim 3: Estimate the influence of factors identified in Aim 1 on PCPs’ decisions to 
recommend e-cigarettes to their patients; 
Aim 4: Evaluate the conceptual model which demonstrates the factors contributing to 
PCPs’ decisions to recommend e-cigarettes to their patients.  
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Chapter 2: Primary Care Physicians’ Beliefs and Practices Regarding E-
cigarette Use by Patients Who Smoke: A Qualitative Assessment 
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ABSTRACT 
Background: There is growing evidence that e-cigarettes are being discussed and recommended 
during physician office visits. Factors underlying these conversations and physician 
recommendations regarding e-cigarette use remain unknown. Objective: To explore primary 
care physicians’ (PCPs’) beliefs and practices about e-cigarettes. Design: Cross-sectional, semi-
structured interviews with PCPs in 2014 were conducted and audio-recorded. Study Population: 
Participants were 15 general internal medicine and family practice physicians practicing in two 
settings in Virginia, USA. Coding and Analysis: Interview recordings were transcribed, and the 
content analyzed using the constant comparative method to identify key themes regarding PCPs’ 
reported current practices and beliefs. Results: Five themes were identified:  PCPs report 1) 
noncombustible tobacco products (such as e-cigarettes) receive little proactive screening 
attention within existing clinic processes, 2) patients commonly initiate e-cigarette discussions, 
and seek physician guidance regarding e-cigarette use, 3) a lack of knowledge regarding the 
potential harms and benefits of e-cigarettes, 4) believing e-cigarettes are a safer alternative to 
smoking combustible tobacco products, and 5) abandoning concerns regarding the potential 
harms of e-cigarettes in the context of highly addicted patients and those with extensive 
comorbidities. Limitations: Physician practices and beliefs are reported from two primary care 
practices and ability to generalize study findings may be limited. Conclusions: Despite 
acknowledging limited knowledge regarding e-cigarettes, findings suggest that some primary 
care physicians are currently recommending e-cigarettes to their patients for smoking cessation 
and relative harm reduction, often personalizing recommendation based on the patient’s 
perceived level of addiction and current health status. Physicians need to be informed about the 
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evolving evidence regarding the risks and benefits of e-cigarettes to be able to competently steer 
e-cigarettes-related discussions with their patients.  
Abbreviations 
US   United States 
PCP  Primary Care Physician 
FDA  Food and Drug Administration 
ACORN  Ambulatory Care Outcomes Research Network 
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INTRODUCTION 
A wide range of new and emerging tobacco products are thriving in the United States 
(US) despite limited knowledge of their health implications.2, 29 One such product, the e-
cigarette, is marketed as a cessation aid, harm reduction strategy or both.2, 4 As evidenced by a 
number of recent studies, experimentation, use, and promotion of e-cigarettes have been growing 
exponentially over the past few years.6, 24, 29, 92 Despite this growth, how e-cigarettes are 
perceived by physicians is not fully understood.31, 32 
 National clinical organizations such as the American Heart Association,59  American 
Association for Cancer Research and the American Society of Clinical Oncology60 have recently 
issued policy statements  regarding e-cigarettes, advocating that physicians screen for the use of 
e-cigarettes, but continue to recommend only Food and Drug Administration (FDA)-approved 
pharmacotherapies for cessation. Most recently, the US Preventive Services Task Force 
continued to support the use of only FDA-approved pharmacotherapies for cessation, and not e-
cigarettes, citing a lack of sufficient evidence surrounding e-cigarette potential to aid with 
smoking cessation.61  
With the absence of either a comprehensive set of recommendations from professional 
organizations or regulatory actions from the FDA,86 physicians are likely to rely on their own 
perceptions when discussing e-cigarette use with their patients who smoke. Current evidence 
suggests that e-cigarettes are being discussed in physicians’ offices in multiple settings.31-33, 77  
Yet, to our knowledge, there are only two examples of published reports that include US-based 
primary care physicians (PCPs).32, 33 Both reports rely solely on data from physician surveys, and 
found that patients actively solicit their PCP’s opinions regarding e-cigarettes. Despite these 
studies, how PCPs approach e-cigarette discussions, and the full range of factors that contribute 
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to their beliefs, perceptions and decisions to recommend e-cigarettes remain largely unknown.31, 
32  
The purpose of this study is to describe PCPs’ current tobacco use screening behavior as 
it pertains to e-cigarettes, identify PCPs’ current approaches to tobacco use cessation counseling 
as well as to explore their beliefs and practices about e-cigarettes, and to understand the context 
in which they might recommend e-cigarette use to their patients who smoke. 
 
METHODS  
Study Participants 
Participants were family and general internal medicine physicians employed by a large 
university health system in Richmond, Virginia, supplemented by an additional sample of family 
medicine physicians practicing in the Virginia Ambulatory Care Outcomes Research Network 
(ACORN) located in northern Virginia. ACORN is a network of family medicine, internal 
medicine, paediatrics, nursing or other specialties with a mission to improve health and 
transform care delivery through primary care research and implementation.93 We purposefully 
sampled from different practice settings to ensure that sampled physicians treated heterogeneous 
patient populations across a diversity of settings and geographic areas in Virginia.  In April of 
2014, we contacted all family and general internal medicine physicians working at the university 
health system (N=46) via e-mail to invite them to participate in the study. In July 2014, we 
invited another (n=40) family medicine physicians practicing in two ACORN clinics. To be 
eligible for participation, physicians had to report providing outpatient primary care to adult 
patients and discussing tobacco use with at least one of their patients within the past 30 days. 
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Participants did not receive any compensation for participation. All aspects of the study were 
approved by the Institutional Review Board of the Virginia Commonwealth University.  
 
Data collection 
After providing written informed consent (Appendix 1), demographic and practice 
information (i.e. age, gender, race/ethnicity, primary speciality, weekly patient volume and year 
of training completion) was collected from each participant. Each PCP then participated in an in-
depth, semi-structured interview. The interview guide was designed to elicit a) current tobacco 
use screening and counselling practices, b) perceptions of and beliefs regarding e-cigarettes and 
c) their screening and counselling practices surrounding e-cigarettes. For the current analyses we 
focused on responses to nine questions (See Figure 2: Text Box). All interviews were conducted 
in person by the study PI (O.S.) between April and August, 2014 at the PCPs’ offices. Interviews 
were audio-recorded, and ranged between 23 and 55 minutes. Prior to analysis all interviews 
were transcribed verbatim.  
Coding and Analytic Methods 
Prior to coding, names and other identifying information were removed from transcripts. 
Transcripts of audio-recorded interviews were analyzed using the constant comparative method 
proposed by Glaser.94 The research team (O.S., R.B., J.E.L) conducted bi-weekly meetings 
during which themes were identified and discussed. A consensus process was used to achieve 
agreement on the inclusion of themes. Initially, as the methodology requires, a first set of 
transcripts (n=5) was analyzed. Once an exhaustive analysis of this original data set was 
complete, further sub-samples of transcripts were analyzed at a time until no additional themes 
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were identified. The themes which emerged from these data were compared with those from the 
original data set and if necessary, new thematic categories were defined. This process continued 
until no new themes emerged. No further interviews were needed to be conducted after the 15th 
interview. The emerging themes were intended to be descriptive of PCPs’ behaviors during 
tobacco use cessation counseling with their patients who smoke and their beliefs regarding e-
cigarettes. This iterative process resulted in further refinement of the themes: reported themes 
were agreed upon by the three authors. 
 
1. How do you typically ask your patients to find about their tobacco use 
status? 
2. How do you go about counselling patients who are current tobacco users? 
3. Have you ever asked any of your patients about their e-cigarette use? 
If yes, “How did you go about doing that?” 
4. Have any of your patients ever asked you about e-cigarettes? 
If yes, "Can you estimate how often over the past year?” AND 
“Can you tell me a typical question patients asked?” 
5. Do you know if any of your patients use e-cigarettes? 
If yes, " What are your thoughts about that? 
6. Did you recommend e-cigarettes to any of your patients? 
If yes continue probing Was there something specific about the 
patient that led you to recommend/NOT recommend it? What was it 
about the patient? Something they said? 
7. What are your thoughts regarding e-cigarettes and other modes of tobacco 
use?  > How do you think e-cigarettes compare to other tobacco use 
available? 
8. What are your thoughts regarding e-cigarettes and smoking cessation?  > 
How do you think e-cigarettes compare to other cessation aids available? 
9. Are there specific patients that you might be more or less likely to 
recommend e-cigarettes to? >Give me an example of patient you are more 
likely/least likely to recommend e-cigarettes for. 
 
Figure 2: (Text Box) Semi-structured Interview Questions with Main Probes Used 
  
 
 
19 
 
RESULTS 
Study Population  
Fifteen PCPs, seven from the university health system and eight from ACORN consented 
to participate in the study. Eleven participants were family medicine physicians and four were 
general internal medicine physicians. The mean age of participants was 43.1 years (SD=+10.3) 
and on average they had been practicing for 15.4 years (SD=+10.6). PCPs were evenly 
distributed by gender (i.e., 53% male and 47% female), and were predominantly white (60%) or 
Asian (20%). The average patient volume was 63.2 patients per week (SD=+31.9).   
Themes  
Thirteen PCPs reported discussing e-cigarettes with their patients; of those, six reported 
having previously recommended e-cigarette use to at least one of their patients. Five overarching 
themes emerged from the qualitative analysis: 1) PCPs acknowledge that noncombustible 
tobacco products (such as e-cigarettes) receive little proactive screening attention within existing 
clinic processes, 2) PCPs report that patients commonly initiate e-cigarette discussions, and seek 
physician guidance regarding e-cigarette use, 3) PCPs express a lack of knowledge regarding the 
potential harms and benefits of e-cigarettes, 4) PCPs believe that e-cigarettes are a safer 
alternative to smoking combustible tobacco products, and 5) PCPs’ concerns regarding the 
potential harms of e-cigarettes are abandoned in highly addicted patients and those with  
extensive comorbidities. Each theme is described below with illustrative interpolations from 
transcript data. 
  
 
 
20 
 
Theme 1:  PCPs acknowledge that noncombustible tobacco products (such as e-cigarettes) 
receive little proactive screening attention within existing clinic processes. 
While participating PCPs reported established processes to screen for combustible 
tobacco products, none reported a similar process for new and emerging tobacco products, 
including e-cigarettes. There were multiple office-based processes reported to screen for patient 
smoking status. Generally, these processes started with nursing staff screening for use and 
documenting results in the electronic health record for later PCP follow up during office 
discussions. Most PCPs indicated that they ask about their patients’ smoking status as part of 
their routine screening process, but do so without probing into smokeless tobacco products – 
“Typically we’ll ask as part of the routine 
screening, but I will admit that for most routine 
visits, I generally don’t probe into smokeless 
tobacco products.” [PCP A] 
PCPs also reported particularly not screening for e-cigarette use – 
“I don’t ask specifically about smokeless tobacco, 
chewable tobacco, e-cigarettes.  It’s generally just 
‘Do you smoke?’ or ‘Were you a smoker in the 
past?’ and then ‘How much, over what period of 
time?” [PCP B] 
Some of the PCPs expressed having less concern about noncombustible tobacco products –  
“Usually lesser for some reason that I am worried 
about chewing tobacco or snuff. I don’t ever 
specifically ask about e-cigarettes. So, 90% of 
patients I ask the question “do you smoke?” and 
leave it at that.” [PCP C] 
However, a few PCPs reported probing for different tobacco products–   
“I ask them if they’re smoking, but then generally 
I’ll also get down to then ‘Are you chewing?  Are 
you using the dip?” [PCP D], 
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and with exception of one physician, none of those PCPs reported ever probing for e-cigarette 
use. 
Theme 2:  PCPs report that patients commonly initiate e-cigarette discussions, and seek 
physician guidance regarding e-cigarette use. 
PCPs consistently expressed that it is patients who usually initiate e-cigarette 
discussions–  
 “E-cigarettes have definitely been coming up in the last 
six months. I would say maybe the last year, but in the 
last six months more and more patients are mentioning 
it as an alternative or something they are looking to 
instead of traditional smoking.” [PCP E] 
Furthermore, patients’ expression of interest was expressed to be a primary reason for a PCP to 
recommend them for smoking cessation– 
“I believe in patient-centered care, and I think that 
changing your health behaviors is really hard.  So 
whatever my patient thinks is going to help them with 
quitting smoking, I would support, and that would 
include e-cigarettes, if they wanted to do that.” [PCP F] 
The salience of patients’ interest in trying e-cigarettes was common across all PCPs, both those 
who recommended e-cigarettes to their patients–  
“If they bring it up and they have a motivation I’m 
usually very encouraging.”  [PCP A], 
and those who had not previously recommend e-cigarette use to their patients prior to the study–  
“Somebody who comes to me and specifically says, 
I am thinking of switching then the patient 
preference would be a factor in this case.” [PCP G] 
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For some PCPs, discussion of e-cigarettes was reported as relatively frequently 
“E-cigarettes come up all the time now, sometimes 
our patients have started doing them on their own, 
or they have friends who are doing them and they 
ask about them, so they come up pretty routinely 
now.” [PCP D] 
Theme 3:  PCPs express a lack of knowledge regarding the potential harms and benefits of    
e-cigarettes.  
Regardless of whether a PCP had recommended e-cigarettes, all expressed a lack of 
knowledge about e-cigarette safety and their efficacy as a smoking cessation aid.  One PCP who 
had not recommended e-cigarette use said–  
“The safety is not listed there and you don’t know 
what they’re actually putting into it.  They may not 
be labeling it correctly and that you may be putting 
other carcinogens in yourself and maybe you’re not 
getting as much smoke, but there are other things 
that you’re getting.” [PCP H] 
On the other hand, a PCP who had previously recommended e-cigarettes said– 
“I wouldn’t say it’s safe, because nicotine can make 
your heart rate go up, and vaso-constrict, if 
somebody takes the e-cig and takes 30 or 40 puffs in 
a row, that’s probably not good for their coronary 
vasculature. So I guess in certain ways you could 
have more harm to the heart than a regular 
cigarette, perhaps, in certain situations.” [PCP I] 
With regards to the efficacy of e-cigarettes for smoking cessation, one PCP commented on the 
need for scientific evidence and commented that such evidence regarding e-cigarettes is lagging 
behind that for other established FDA-approved pharmacotherapies by saying–  
“I want to see a research study that shows that 
that’s helped.  There are great research studies with 
Chantix, with Wellbutrin, with patches and with 
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doctors’ counseling.  So we know that patients on 
average, 7% of patients quit smoking just on their 
own volition.  If you start adding things like Chantix 
and Wellbutrin, you can get it up to 15 to 23%.  I 
want to see a study like that, that randomizes people 
to e-cigarettes versus Chantix, versus patches, 
versus doctors just telling people to quit smoking, 
and when I see that, then I’ll say it’s an effective 
means of helping people quit, but there’s no data on 
that.  It has to be studied.” [PCP F] 
Moreover, PCPs expressed not only that they have a lack of knowledge but that there is not yet 
enough information regarding e-cigarettes and that it is not easy to find such information by 
saying–  
“I tell them is that we don’t have a lot of data on 
the e-cigarettes because they’re not FDA-regulated 
yet and so individual safety data is complicated.  
The only stuff I’ve been able to find is from the 
manufacturers and some Australian stuff, and of 
course that’s all done by the people that sell the 
cigarettes. So, I just give them all the information 
that we have, which is not much, and if they want to 
try it, I say I don’t really have a strong objection to 
you doing that.” [PCP D] 
Theme 4:  PCPs believe that e-cigarette use is a safer alternative to other tobacco products. 
All PCPs expressed concerns about the potential harms of e-cigarette use. However, most 
PCPs expressed that e-cigarette use is likely safer than the use of traditional tobacco products – 
“I think, in general taken as a whole, they’re safer than smoking, chewing 
tobacco, pipes, cigars probably.” [PCP I] 
Most of the PCPs used cigarette smoking as the benchmark for establishing a comparison for e-
cigarettes’ safety as a nicotine delivery product, one PCP elaborated on this by saying–  
“What I want to know is that they are safer than 
cigarettes, because it’s that risk-benefit thing.  So if 
someone’s already smoking cigarettes, if I can’t get 
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to perfect, which is nothing, and there are some risks 
associated with the inhaled nicotine, but it’s less 
than the inhaled cigarettes, I’ll take the e-cigarettes. 
I can’t imagine it’s not safer than the actual 
cigarettes, because cigarettes are just known to be 
bad for you in so many ways.” [PCP D] 
In addition to that, PCPs acknowledged that their perception of e-cigarettes 
being safer than other combustible tobacco products, is a factor in their 
recommendation when coupled with the interest of their patient to try e-
cigarettes, one PCP explicitly explained that by saying–   
“There is a perception- kind of automatic response- 
that it must be safer. Because it is not smoking, so 
it’s got to be better than smoking. And what I have 
tried to tell patients is that we don’t actually know 
that to be the case. We don’t know anything about e-
cigarettes in terms of safety, we don’t know if they 
are harmful, we don’t know if they are not harmful, 
we do know smoking is harmful, so I often times let 
patients come to a decision that they are more 
comfortable with” [PCP E] 
However, the same PCP further shared more skepticism about the absolute 
safety with e-cigarettes, while still acknowledging the likely relatively 
safety benefit of e-cigarettes compared to traditional cigarettes by saying– 
“I am very, very skeptical about a lot of it, I think 
it’s being advertised as a safer, healthier 
alternative, I don’t think it is true and if it is, it 
won’t be safe, it will be safer and it still won’t be 
something that is very good for people. The vapor 
from the e-cigarettes has some of the chemicals that 
you find in tobacco smoke, and the liquid itself of e-
cigarettes is incredibly dangerous” [PCP E] 
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Theme 5: PCPs’ concerns regarding the potential harms of e-cigarettes are abandoned in 
highly addicted patients and those with extensive comorbidities. 
PCPs reported recommending e-cigarettes to heavy smokers or to patients with existing 
co-morbidities– 
“ The people who are smoking like a pack a day 
and really chimneys, I’m like you want anything 
that you can do that’s an action that gets in the 
right direction.  So I usually am pretty encouraging 
of it in that setting.” [PCP K] 
In other instances, PCPs were more inclined to recommend e-cigarettes for heavy long-term 
smokers who have previously tried quitting and failed with conventional cessation medications 
and who may be addicted to the social habit of smoking.  For example one PCP said– 
“If somebody said to me, ‘Doc, I’ve already tried 
the gum.  I’ve tried the patches.  It didn’t work for 
me, and I’m not really interested in taking these 
antidepressant medicines that you’ve talked about 
with the craving.  I think I’m just so hooked on the 
physical act of smoking that I think the e-cigarettes 
are going to be a better way for me to bridge to 
using,’ so I would probably recommend e-
cigarettes.” [PCP J] 
Similarly, a PCP acknowledged that recommending e-cigarettes for cessation could be a good 
option for a cessation attempt with patients with smoking related co-morbidities–  
“When I think of any therapy that I might 
recommend to someone without really feeling like 
it’s super well-established or that I really understand 
all the risks and benefits, it’s like people who stand 
the most to gain by using it, so people who are like 
long-term smokers or who I know will do really 
poorly with some of the medications or other options 
that are out there, people who I just think 
behaviorally would be more amenable to something 
like that, I guess those would be the people that I 
would think more of using it” [PCP K]. 
 
 
26 
 
DISCUSSION 
Five themes emerged in our current study and the information within these themes 
suggests that despite routine screening for conventional tobacco use, screening for e-cigarette use 
seems not to be yet established in primary care. However, smokers and their physicians 
frequently discuss e-cigarettes during primary care office visits. Although PCPs report not 
typically initiating these e-cigarette discussions, citing a general lack of knowledge regarding the 
potential benefits and harms of e-cigarettes, they nonetheless perceive e-cigarettes to be a safer 
alternative to other tobacco products, particularly combustible cigarettes. Furthermore, some 
PCPs acknowledge recommending e-cigarettes to at least some of their patients who smoke. 
They tend to be more likely to recommend e-cigarettes for harm reduction and smoking cessation 
to certain patient profiles including those thought to be highly addicted to smoking, whose 
current health status is perceived as warranting immediate action, and who have had a prior 
failed quit attempt using FDA-approved pharmacotherapies. Moreover, patients’ interest in 
trying e-cigarettes appeared to be a particularly salient facilitator in PCPs’ decisions to 
recommend e-cigarette use. 
Faced with little empirical evidence,2, 60 difficulty finding  relevant risk/benefit 
information, and a void in professional guidelines,62 PCPs seem to be developing their own 
approaches to incorporating e-cigarette use into their reportedly increasing patient inquires about 
e-cigarette use ,31-33 and tobacco use related counseling. Prior research31-33 has shown that PCPs 
in general believe that e-cigarettes are safer than traditional cigarettes. While PCPs in our study 
share that belief, they were less consistent in acknowledging the efficacy of e-cigarettes as a 
smoking cessation aid. Nonetheless, most PCPs in our sample reported being more willing to 
recommend the use of e-cigarettes to patients they perceived as highly addicted or those with 
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extensive smoking-related comorbidities than to other smokers. Because such recommendations 
are being made despite PCPs’ overall skepticism regarding the efficacy of e-cigarettes as a 
smoking cessation aid, this suggests that PCPs’ willingness to recommend e-cigarettes may be 
driven by their belief in e-cigarettes’ capacity for relative harm reduction.  
Our results indicate that, in spite of PCPs uncertainty about e-cigarettes, they are 
recommending them to patients and these recommendations are supported by patient interest in 
trying e-cigarettes. Thus PCPs in our study seemed to adopt a patient centered approach when 
communicating with their patients about e-cigarettes.95 When patients raised the topic of e-
cigarettes, PCPs reported explaining the limited information they know about e-cigs, and actively 
supporting a patient’s decision to try them. In fact, it is plausible to suggest that patients are a 
likely source of information for PCPs about e-cigarettes and may be indirectly driving PCPs’ e-
cigarette beliefs and practices. Yet, it is also likely that patient and physician e-cigarette 
knowledge is directly influenced by industry marketing and advertising as well as lay press 
publications regarding the evolving market of e-cigarettes.31, 96 This coupling of indirect and 
direct influence on PCPs is reminiscent of the influence of historical conventional tobacco 
advertising, but is differentiated by the aid of the global spread afforded by social media.97, 98 
Despite recommendations to screen and counsel patients for e-cigarette use,59, 60 
expecting most PCPs to proactively do this is likely unrealistic given the void in relevant 
evidence to help PCPs steer a conversation once patients’ use of, or interest in using, e-cigarettes 
is established. Instead, it appears that increasingly frequent office-based interactions regarding e-
cigarettes are causing PCPs to develop non-evidence based opinions and then use those opinions 
in their routine tobacco use cessation counseling to address their patients’ inquiries about e-
cigarettes. Despite the FDA and many researchers racing to fill these evidence voids, the reality 
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is that it will take many years before we understand the full range of public health benefits and 
risks associated with e-cigarettes,29, 61 and thus the health and other implications of current PCP 
beliefs and practices regarding e-cigarettes.  
Limitations 
The results of our study should be interpreted in the context of several limitations. First, 
study data were collected between May and August of 2014, and given the rapidly evolving e-
cigarette market the applicability of findings to today’s practices should be interpreted with 
caution. Second, PCPs interviewed were limited to those practicing within two Virginia settings 
and included only a small number of the potentially eligible physician subjects within these 
settings. As such, care should be taken when generalizing findings to other settings and 
providers. Nevertheless, to our knowledge this is the first study to use qualitative research 
methods to assess comprehensively PCPs’ beliefs and practices regarding e-cigarettes and 
articulates underlying reasons behind PCPs’ recommendations of e-cigarettes.  
CONCLUSION 
In conclusion, PCPs expressed a lack of information about e-cigarette safety and efficacy 
along with skepticism about the role of e-cigarettes in tobacco control in general and in smoking 
cessation in particular. However, once a patient initiates a discussion with them, PCPs seem to be 
endorsing patients’ interest in using e-cigarettes, as well as recommending e-cigarettes to 
particular types of patients who smoke for both smoking cessation and as a harm reduction 
strategy. Such findings serve to illustrate the importance of generating and rapidly disseminating 
evidence regarding e-cigarette safety and efficacy for smoking cessation to US physicians.  
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Without such effort, PCPs will continue to devise their own beliefs and practices regarding e-
cigarettes that are likely to be difficult to change once established.99   
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Chapter 3: Physicians’ Knowledge, Beliefs and Practices Regarding E-
cigarettes: Results from a national survey of US primary care physicians 
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ABSTRACT 
Background:  E-cigarette use is exponentially increasing in the United States despite limited 
knowledge about their potential harms or benefits. Objective: To understand the extent to which 
PCPs report e-cigarette discussions and recommendations as well as their knowledge and beliefs 
regarding e-cigarettes and how these influence their propensity to recommend e-cigarettes to 
their adult patients who smoke. Methods: We used a modified Dillman approach to administer a 
mailed survey to a national random sample (N=1430) of office-based primary care physicians 
(PCPs) between February and May, 2015. Survey content was informed by existing literature 
and qualitative research. Chi-square tests and t-tests were used for bivariate analysis, as 
appropriate to compare PCPs who recommend and do not recommend e-cigarettes. M-Plus with 
full information likelihood estimation was used to identify factors associate with PCPs who 
reported previously recommending e-cigarettes. Results: 328 PCPs returned the survey for a 
24% response rate. 82.7% of eligible PCPs (n=220) reported previously discussing e-cigarettes 
with their patients and 57.8% (n=155) reported previously recommending e-cigarettes to their 
patients who smoke. The majority reported recommending them for smoking cessation and harm 
reduction (71.6%, n=111), 19.2% for smoking cessation only, and 9.6% for harm reduction only. 
PCPs’ knowledge regarding e-cigarettes, particularly potential harms, was low, but beliefs 
regarding e-cigarettes ability to help in quitting smoking and to help limit secondhand smoker 
exposure to others, decreasing cancer risk and the perception that e-cigarettes offer a relative 
harm reduction tool compared to other tobacco products was high. Patients’ interest in using e-
cigarettes (odds ratio=1.31, 1.09-1.58) and the PCP having favorable beliefs regarding e-
cigarettes ability to help in quitting smoking (odds ratio=1.80, 1.45-2.24),  to limit secondhand 
smoke exposure for others (odds ratio=1.45, 1.15-1.83), to reduce harm compared to other 
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tobacco (odds ratio=1.11, 1.05-1.16), and deter patients from using conventional cessation 
medications (odds ratio=0.78, 0.64-0.95) were associated with PCPs’ reports of previously 
recommending e-cigs to their patients who smoke Limitations: Having a low response rate and 
potential for response bias limit ability to generalize beyond sample. Conclusion: Results 
illustrate an opportunity to improve PCPs’ e-cigarette-related knowledge while their practice is 
still developing. The impact of improving PCPs’ knowledge on their recommendations is 
unknown. However, once their practice is established it is difficult to change. 
Abbreviations 
US   United States 
PCP  Primary Care Physician 
AMA  American Medical Association 
GIM  General Internal Medicine 
FP  Family Practice 
GP   General Practice 
FDA  United States Food and Drug Administration 
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INTRODUCTION 
E-cigarette use has been increasing exponentially in the United States (U.S.) among 
smokers and non-smokers alike.20, 22, 24, 29, 92, 98 Although, e-cigarettes have been marketed as 
both a harm reduction strategy and as a smoking cessation aid,22, 29, 92, 98 evidence regarding e-
cigarette safety and their efficacy as a smoking cessation aid is still emerging.22, 32, 61 E-cigarette 
use has been linked to a steep increase in calls to poison centers, mostly among children (ages 0-
5), in the US between 2012 to 2014 to report side effects due to inhalation or skin contact like 
nausea or vomiting.100 As of yet,  e-cigarettes has not been linked directly to any serious adverse 
events;101 however, the liquid nicotine used in e-cigarettes can contain  some of the toxicants and 
carcinogens found in traditional cigarettes,40, 41, 102-104 and studies suggest that e-cigarette use can 
cause acute adverse pulmonary effects.105, 106 Moreover, the amount of nicotine delivered by e-
cigarettes varies greatly from no nicotine to levels higher than that found in conventional 
cigarettes.12, 13, 35 Furthermore, while some early studies point to the potential for e-cigarettes to 
serve as an effective smoking cessation aid, 37, 38, 51, 52, 107 many such studies have been industry 
sponsored and/or criticized for their methodological limitations.37, 38, 52 
E-cigarette production and marketing are not currently regulated by the U.S. Food and 
Drug Administration (FDA),36, 108 and the US Preventive Health Services Task Force recently 
concluded that there was insufficient evidence to recommend their use as a smoking cessation 
aid.61 National clinical organizations such as the American Heart Association,59 the American 
Association for Cancer Research, and the American Society of Clinical Oncology60 have issued 
position statements regarding e-cigarettes. These organizations generally have advocated that 
clinicians screen for the use of e-cigarettes, but offer little guidance once e-cigarette use is 
identified,59-61 advising only that physicians share the limited evidence base regarding their 
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safety and efficacy while continuing to recommend FDA-approved pharmacotherapies for 
smoking cessation.59-61  
Given the limited guidance from national  clinical organizations and the general lack of 
conclusive evidence regarding either the full health implications of e-cigarettes or their efficacy 
in smoking cessation,2, 29, 31 physicians may be relying on their patients, the e-cigarette industry 
and information in the lay press as sources of e-cigarette-related information.31 Recent finding 
suggest that patients are seeking advice from their physicians regarding e-cigarette use and that 
some physicians are recommending e-cigarettes to their patients who smoke.8, 30, 31 Physicians 
and patients alike, seem to believe that e-cigarettes can help with quitting,2, 8, 30-32 and are less 
harmful in comparison to conventional cigarettes.17, 31-33, 92 Our own qualitative study found that 
despite acknowledging limited evidence regarding the benefits and risks associated with e-
cigarettes, some primary care physicians (PCPs) recommend e-cigarettes to their patients who 
smoke for both smoking cessation and harm reduction purposes.109 Furthermore, we found that a 
PCP’s propensity to recommend e-cigarettes to a given patient seemed to be influenced by that 
patient’s interest in trying e-cigarettes.  
Despite insights from such studies, it remains uncertain how PCPs, who currently deliver 
the vast majority of office-based physician tobacco use cessation counseling,63, 64, 79 are 
incorporating e-cigarettes into their counseling practices and what factors might be influencing 
this incorporation. To address this knowledge gap, we surveyed PCPs nationwide to understand 
the extent to which they report e-cigarette discussions and recommendations as well as their 
knowledge and beliefs regarding e-cigarettes and how these influence their propensity to 
recommend e-cigarettes to their adult patients who smoke.   
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METHODS 
Sample Selection 
Using the American Medical Association’s (AMA’s) Masterfile, we identified a sample 
of General Internal Medicine (GIM), Family Practice (FP) or General Practice (GP) physicians 
aged 75 years or younger actively delivering office-based care.  We contacted a random sample 
of N=1,430 PCPs supplied by an authorized vendor of the AMA’s 2015 Masterfile (Medical 
Marketing Service, Schaumburg, IL; 2015).  
Survey Development and Administration 
The survey included items adapted from validated instruments of clinicians’ tobacco use 
cessation counseling beliefs and practices,80, 110 and those specific to e-cigarette beliefs and 
practices developed from results of our qualitative research.109 It also included e-cigarette-related 
knowledge items developed in consultation with a leading expert in e-cigarette toxicity and 
regulatory policy. Once developed, the survey was refined in response to comments from five 
experts in psychometrics and patient-provider communication. The instrument also was pretested 
for clarity and ease of understanding via semi-structured cognitive interviews with a convenience 
sample of 10 PCPs practicing in an academic medical center; those PCPs provided an informed 
consent for participation and received no compensation (Appendix 2). The final 32-item 
questionnaire took approximately 15-20 minutes to complete, and was administered via the US 
postal service using a Dillman process111  between February and May 2015 (Appendix 3). All 
correspondence, except for the postcard, was signed by the study PI (O.S.). As a token of 
appreciation, physicians who retuned the survey received a $10 gift card to a retailer of their 
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choice. All aspects of the study were approved by the Institutional Review Board at the Virginia 
Commonwealth University.  
Measures and Variables 
E-cigarette recommendations 
Our main outcome variable was whether or not the PCP reported previously 
recommending e-cigarettes for smoking cessation, harm reduction or both to his/her adult 
patients who smoke. We categorized PCPs as “never” versus “ever” recommending e-cigarettes, 
regardless of reason for recommendation. We also ascertained PCP-reported e-cigarette 
discussion frequency and initiation. For the latter, response categories were: I usually raise the 
topic, my patients usually raise the topic, and it is equally as likely that I or my patients raise the 
topic. An additional item was used to assess the extent to which PCPs considered patients’ 
interest in trying e-cigarettes when recommending e-cigarettes by asking whether patient’s 
interest is/would be a primary reason for recommending e-cigarettes (Strongly Disagree to 
Strongly Agree) and was scored from one to seven. 
Knowledge about e-cigarettes 
Five items assessed PCPs’ knowledge regarding e-cigarettes. One item assessed whether 
e-cigarettes are currently regulated by the FDA. Two were risk-related: the nicotine liquid used 
in e-cigarettes can contain carcinogens and e-cigarettes can adversely affect lung function. Two 
items were product feature-related: some e-cigarettes can deliver more nicotine than traditional 
cigarettes and some e-cigarette brands do not deliver nicotine. Responses were true, false or I 
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don’t’ know. For analyses these variables were coded as a three-level categorical variables or as a 
binary variable (correct versus otherwise). 
Beliefs about e-cigarette  
PCPs’ e-cigarette beliefs were assessed using five 7-point Likert scale items (Very 
Unlikely to Very Likely). For example, we assessed whether PCPs believed e-cigarettes can help 
patients quit smoking. An additional belief item assessed whether the PCP believed e-cigarettes 
can create dual tobacco users (Strongly Disagree to Strongly Agree).  
We also asked PCPs to rate how harmful e-cigarettes and five other tobacco products are 
to the health of their patients using a 7-point Likert scale (Not at All Harmful to Extremely 
Harmful). The products were traditional cigarettes; tobacco pipes; waterpipes [hookah or 
narghile]; cigars, cigarillos and little cigars; and smokeless tobacco. We constructed 5 items to 
assess PCPs’ perceived reduced harm of e-cigarettes relative to these other products by 
subtracting their e-cigarette score from each of the other scores. For each constructed item, a 
positive score indicated relatively less harm, zero indicated equal harm, and a negative score 
indicated relatively more harm. A total relative harm reduction score was produced by summing 
the resulting scores across the five items (Cronbach α=0.93). 
Counseling self-confidence 
PCPs were asked to indicate their confidence in two items: their ability to counsel 
patients about tobacco use in general and their ability to counsel patients about e-cigarettes use 
by indicating their level of agreement using a 7-point Likert scale (Strongly Disagree to Strongly 
Agree).  
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Other physician characteristics 
The survey included questions regarding PCPs’ practice setting (i.e. practice size, average 
number of patients seen per week, and percent of professional time spent providing care to adult 
patients). It also included prior training in smoking cessation counseling, whether or not PCPs 
had a medical school affiliation, and demographic characteristics (gender, age and year of 
residency completion). Information on clinical training (Medical doctor vs Doctor of 
Osteopathy), specialty (GIM, FM, and FP), board certification, medical school training (US 
versus foreign) and geographic practice region were ascertained from the AMA Masterfile.   
Statistical Analysis  
Descriptive statistics were used to characterize the sample. Prior to conducting analyses, 
we assessed item non-response, finding it not to exceed 3.3%. Nonetheless, M-Plus with full 
information likelihood estimation was used for inferential analyses.  Differences in physicians 
who reported recommending e-cigarettes compared to those who reported not recommending e-
cigarettes were tested using Chi-square tests and t-tests, as appropriate. For categorical variables 
(i.e. knowledge items), when an overall Chi-square test established statistical significance, the 
Wald test of parameter constraints was used to test for pairwise differences. For the multiple 
logistic regression model testing, we included PCPs’ e-cigarette beliefs, knowledge, and their 
consideration of patient interest in trying e-cigarettes, controlling for PCPs’ gender, age, years of 
practice, specialty, board-certification, medical school training, geographic location, number of 
patients per week, percentage of time providing care to adult patients, practice size, having an 
academic affiliation, having had a prior training in smoking cessation counseling, their 
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confidence in their ability for tobacco use counselling in general and for e-cigarettes in 
particular. Variables were considered statistically significant at p<0.05.  
Prior to initiating analyses, the representativeness of PCP respondents in terms of age, 
gender, clinical training, specialty and practice region was assessed using z tests of differences in 
proportions. No significant differences were found between survey respondents and PCPs in the 
AMA Masterfile except for PCPs’ specialty. Survey respondents disproportionately were FP 
physicians (57.9% vs. 49.1%) and not GIM physicians (39.2% vs. 48.0%). We therefore used a 
post stratification weight (GIM=1.2, FP=0.84, and GP=1) to match the proportions in the AMA 
Masterfile. 
RESULTS 
Sample Characteristics 
A total of 328 surveys were returned. Among those, 50 were ineligible (37 not in direct 
patient care, seven not in primary care, and six retired). The survey response rate, adjusted for 
ineligible cases, was 24%.112 The final weighted sample size was 274 PCPs (Table 2). Most 
survey respondents were males (62.9%). Mean years of practice was 19.9 (+11.1). The majority 
spent at least half of their time providing care to adult patients (84.5%). Most were board 
certified in either GIM or FM (83.2%), and 79% attended medical school in the US. 
Approximately a third reported prior training in smoking cessation counseling (33.8%) or had an 
affiliation with a medical school (36%). Sample PCPs reported having higher self confidence in 
counseling patients on conventional tobacco use (M=6.3) relative to e-cigarettes-related 
counseling (M=4.3).  
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Table 2: Physician Characteristics: Overall and by E-cigarette Recommendation Status 
Physician Characteristic 
All 
(N=274)† 
Recommenders 
(n=155) 
Non-Recommenders 
(n=114) 
DEMOGRAPHICS AND CLINCAL 
TRAINING 
     Gender (%)* 
   
 Male  62.9 68.4 55.8 
 Female 37.1 31.6 44.2 
     Years of Practice (mean, SD) 19.9 (+11.1) 20.2 (+10.9) 19.8 (+11.4) 
     Age (mean, SD) 52.2 (+10.7) 52.1 (+10.6) 52.4 (+10.7) 
     Board-certification (%)    
 Yes 83.2 84.6 16.8 
 No 16.8 15.4 18.6 
     Specialty (%)    
 Family or General Practice  52.3 50.6 54.4 
 General Internal Medicine 47.7 49.4 45.6 
     Medical school training (%)    
 United States 79.0 76.9 82.5 
 Foreign Medical School 21.0 23.1 17.5 
CLINICAL PRACTICE INFORMATION 
     Geographic region (%) 
   
 North-East 17.6 18.1 17.5 
 South 34.4 38.7 29.8 
 Midwest 24.9 22.6 27.2 
 West 23.1 20.6 25.4 
     Practice Size (%)    
 1-2 33.8 37.3 28.6 
 3-10 33.7 33.3 35.7 
 11 or more 32.5 29.4 35.7 
     Mean number of patients/week (mean, SD)** 81.3 (+35.5) 87.5 (+32.7) 74.5 (+37.4) 
     Time providing care to adult patients (%)    
 Less than 49% 15.5 12.9 18.6 
 50-75% 19.5 20.1 18.6 
 More than 75% 65.0 66.9 62.8 
     Academic Affiliation (%)    
 Yes 36.0 33.1 42.0 
 No 64.0 66.9 58.0 
TOBACCO USE COUNSELING 
CHARACTERISTICS 
     Trained in smoking cessation counseling (%) 
   
 Yes 33.8 30.1 39.5 
 No 66.2 69.9 60.5 
     Confidence in ability for tobacco use 
     counseling in general (mean, SD) 
6.3(+1.1) 6.3(+1.1) 6.3(+1.0) 
     Confidence in ability for e-cigarette use 
     counseling (mean, SD) *** 
4.3(+1.9) 4.6(+1.7) 3.8(+2.2) 
† There were 5 missing entries from the recommendation status variable  
* Significant difference by gender (χ2=4.48, p=0.034) 
** Significant difference by mean number of patients/week (t(263)=-3.03, p=0.003) 
*** Significant difference by confidence in e-cigarette counseling (t(263)=-0.78, p=0.001)  
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E-Cigarettes Recommendations 
Over three-quarters (82.7%, n=220) of PCPs reported previously discussing e-cigarettes 
with their patients. Among those, 24.7% (n=51) reported discussing e-cigarettes rarely with their 
patients, 53.2% (n=109) reported discussing e-cigarettes sometimes and 22.1% (n=45) reported 
discussing them often or almost always. Furthermore, while half of the PCPs reported that 
patients usually initiated these discussions (51.2%), 16.2% reported initiating discussions 
themselves, with the remainder reporting that discussions were initiated equally as likely by them 
or their patients (32.6%).  
Overall, 57.8% (n=155) reported previously recommending e-cigarettes to an adult 
patient who smoked. Among those recommending e-cigarettes, the majority reported 
recommending them for smoking cessation and harm reduction (71.6%, n=111), 18.8% for 
smoking cessation only, and 9.6% for harm reduction only. PCPs who reported initiating e-
cigarette discussions more than or equally as likely as their patients were significantly more 
likely to recommend e-cigarettes (84.0%) compared to those who reported that their patients 
usually initiated e-cigarette discussions (55.7%) [χ2(1)=19.47, p<.001]. On average PCPs 
indicated a moderate level of agreement that their patients’ interest in using e-cigarettes 
influenced or would influence their decision to recommend e-cigarettes (mean=4.09, ±1.8), with 
those PCPs who recommend e-cigarettes having a significantly higher level of agreement 
(mean=4.62, ±1.6) compared to PCPs who do not recommend e-cigarettes [mean=3.33, ±1.9; t 
(208.3) =1.29, p<.001]. 
As illustrated in Table 2, there were few significant differences between physicians who 
recommended and did not recommend e-cigarettes. Recommenders were more likely to be male 
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(68.4% vs. 55.8%) and reporting seeing significantly more patients per week (M=87.5 vs. 74.5) 
than non-recommenders.  
Knowledge about E-cigarettes 
Few PCPs (7.6%) answered all 5 knowledge questions correctly. Two-thirds (66.4% and 
65.0%, respectively) of PCPs correctly knew that e-cigarettes are not currently regulated by FDA 
and that some e-cigarette brands can deliver more nicotine than traditional cigarettes (Table 3), 
with the remainder mostly choosing I don’t know (27.2% and 27.8%, respectively). Almost half 
of the PCPs answered I don’t not know for the three other knowledge questions: whether the 
liquid in e-cigarettes can contain carcinogens, e-cigarettes could adversely affect lung function, 
and some e-cigarette brands do not deliver nicotine (44.9%, 54.0% and 47.2%, respectively), 
with only one third answering these questions correctly (36.9%, 32.8% and 36.2%, respectively). 
Those recommending e-cigarettes were more likely to answer the two risk-related items (i.e., e-
cigarettes can contain carcinogens and can negatively affect lung function) incorrectly compared 
to non-recommenders, but other differences in knowledge were not detected by the PCP’s e-
cigarette recommendation status.  
On the other hand, PCPs were more likely to answer knowledge items correctly versus 
otherwise if they had previously discussed e-cigarettes with their patients: 69.5% vs. 41.3% 
correct regarding FDA regulation (p<.001), 70.0% vs. 39.1% regarding delivering more nicotine 
(p<.001), 40.5% vs. 13.0% regarding e-liquid content (p<.001), 40.9% vs. 15.2% regarding 
delivering no nicotine (p=0.001). The one exception was for the lung function question where 
there was no statistically significant difference in correct knowledge by the PCPs’ reported 
discussion status (33% vs. 26%, p=0.35). 
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Table 3: Physician E-cigarette Knowledge Assessment: Overall and by E-cigarette 
Recommendation 
E-cigarette Knowledge Items¥ 
Response 
Assessment (%)
ALL 
N=270†
Recommenders 
n=152 
Non-recommenders 
n=113 
χ2 p-
value 
E-cigarettes are not currently 
regulated by the FDA   
Correct 66.4 68.4 63.7 
0.440 Incorrect    6.4 7.2 5.3 
Don’t Know 27.2 24.3 31.0 
Some e-cigarettes can deliver 
more nicotine than traditional 
cigarettes  
Correct 65.0 71.2 56.5 
0.014* Incorrect    7.1 7.8 6.2 
Don’t Know 27.8 20.9  37.2†† 
The nicotine liquid used in  
e-cigarettes can contain 
carcinogens 
Correct 36.9 38.4 34.8 
0.006* Incorrect 18.3  23.8†† 10.7 
Don’t Know 44.9 37.7 54.5 
E-cigarettes can adversely affect 
lung function  
Correct 32.8 34.2 37.1 
0.002* Incorrect 13.2  19.1†† 5.3 
Don’t Know 54.0 46.7 63.7 
Some e-cigarette brands do not 
deliver nicotine 
Correct 36.2 44.7 24.8 
0.004* Incorrect 16.6 13.8    20.4†† 
Don’t Know 47.2 41.4 54.9 
¥ All items are stated as factually correct 
† There were 5 missing entries from the recommendation status variable  
*Statistically significant via χ2 test (3x2) 
†† Proportion remained significant via Wald test of parameter constraints at p<0.05 (correct responses was the 
reference group).  
 
Beliefs about E-cigarettes  
Overall, PCPs tended to agree with three negative beliefs regarding e-cigarettes (Table 
4): Mean agreement ratings on a 7-point scale were 5.0 (±1.6) for sustaining nicotine addiction, 
4.8 (±1.4) for creating dual tobacco users, and 4.8 (±1.5) for discouraging patients’ use of 
conventional cessation medications. Mean agreement ratings were 5.4 (±1.6) for limiting 
secondhand smoke exposure, 4.2 (±1.6) for decreasing patients’ cancer risk and 4.0 (±1.6) for 
helping smokers quit. In all cases, recommenders held significantly stronger positive beliefs and 
weaker negative beliefs compared to non-recommenders. In general, PCPs’ beliefs did not differ 
by their having correct knowledge regarding e-cigarette. The exceptions were that PCPs with 
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correct knowledge regarding the impact of e-cigarettes on  lung function and that e-liquids could 
contain carcinogens held significantly weaker belief regarding e-cigarettes potential to reduce 
cancer risk (data not shown). 
Table 4: Mean Beliefs Ratings Regarding E-cigarette Use Outcomes: Overall and by E-
cigarette Recommendation Status  
E-cigarettes Use Outcomes  
All 
N=273† 
Mean (SD) 
Recommenders 
n=155 
Mean (SD) 
Non-recommenders 
n=113 
Mean (SD) 
Degrees 
of 
Freedom 
t-test 
p-value 
Limit secondhand smoke exposure 
to patients’ families and friends 
5.4 (±1.6) 5.9 (±1.3) 4.7 (±1.7) 201.8a <.001 
Sustain patients’ nicotine 
dependence 
5.0 (±1.6) 4.8 (±1.4) 5.2 (±1.7) 213.3a 0.036 
Create dual tobacco users 4.8 (±1.4) 4.6 (±1.4) 5.1 (±1.4) 266b 0.005 
Patients are less likely to use 
conventional cessation medications 
4.8 (±1.5) 4.6 (±1.4) 5.1 (±1.7) 265b 0.011 
Decrease patients’ cancer risk 4.2 (±1.6) 4.7 (±1.5) 3.6 (±1.6) 265b <.001 
Help patients quit smoking 3.9 (±1.6) 4.6 (±1.3) 3.0 (±1.6) 207.0a <.001 
† There were 5 missing entries from the recommendation status variable  
a equal variances not assumed  
b equal variances assumed  
SD, Standard Deviation 
The mean score for the overall relative e-cigarette harm reduction measure was 8.6 
(SD=±6.6, range -5 to 30), indicating an overall perception of relative harm reduction.   
Physicians who recommended e-cigarettes on average indicated relatively more harm reduction 
from e-cigarettes (M= 10.7, SD=±6.1) compared to those who did not recommend e-cigarettes to 
their patients (M= 5.8, SD= ±6.1), (t (262) = -4.9, p <.001). 
Logistic Regression Results: Factors Associated with Recommending E-cigarettes  
Controlling for other factors, the more a PCP reported considering their patients’ interest 
in using e-cigarettes, the more likely they were to have recommended e-cigarettes (Table 5):  for 
every point increase in agreement with the statement that they consider their patients’ interest, 
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the likelihood that they recommended e-cigarettes increased by 31%. Similarly, for every point 
increase in a PCP’s belief that e-cigarettes can help in quitting smoking, there was 80% increase 
in the likelihood of the physician recommending e-cigarettes and for every point increase in a 
PCP’s belief that e-cigarettes limit secondhand smoke exposure for others, there was 45% 
increase in the likelihood of the physician recommending e-cigarettes. Likewise, for every point 
increase in a PCP’s perception of e-cigarettes’ relative harm reduction compared to other tobacco 
products, there was an increased likelihood of the PCP recommending e-cigarette use by 11%.  
On the other hand, for every point increase in the PCP’s belief that e-cigarettes would deter 
patients from using conventional cessation medication, there was a 22% reduction in the 
likelihood they recommend e-cigarettes. No other factors were found to be associated with PCPs’ 
likelihood of recommending e-cigarettes.  
Table 5: Multiple Logistic Regression Results: Factors Associated with Physicians’ 
Likelihood of Recommending E-cigarettes (N=274) 
Predictor Variables 
        Standardized 
             Estimate 
OR (95% CI) 
P-
value 
Physician Consideration of Patients’ Interest in Using 
E-cigarettes 
0.173 1. 31 (1.09,1.58) 0.01* 
Physicians’  E-cigarette Belief      
 Limit secondhand smoke exposure to patients’ families and friends 0.209 1.45 (1.15, 1.83) 0.006* 
 Sustain patients’ nicotine dependence 0.021 1.04 (0.85, 1.27) 0.757 
 Create dual tobacco users 0.053 1.11 (0.86, 1.45) 0.492 
 Patients become less likely to use conventional cessation medications    -0.131 0.78 (0.64, 0.95) 0.031* 
 Decrease patients’ cancer risk -0.099 0.84 (0.66, 1.06) 0.213 
 Help patients quit smoking 0.336 1.80 (1.45, 2.24) <.001* 
 Perceived relative harm reduction score 0.230 1.11 (1.05, 1.16) 0.001* 
Physicians’ E-cigarette  Knowledge       
 E-cigarettes are not currently regulated by the FDA      
       Correcta 1     
       Incorrect 0.019 1.26 (0.31, 5.05) 0.78 
       Don’t Know 0.029 1.21 (0.56, 2.56) 0.68 
 Some e-cigarettes can deliver more nicotine than traditional cigarettes      
       Correcta 1     
       Incorrect -0.016 0.83 (0.09, 6.94) 0.88 
       Don’t Know -0.207 0.26 (0.12, 0.54) 0.002* 
 Some e-cigarette brands do not deliver nicotine   
       Correcta 1     
       Incorrect -0.071 0.47 (0.21, 1.51) 0.34 
       Don’t Know -0.093 0.58 (0.30, 1.13) 0.18 
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Table 5: Continued 
Predictor Variables 
        Standardized 
             Estimate 
OR (95% CI) 
P-
value 
Physicians’ E-cigarette  Knowledge (Continued)      
     The nicotine liquid used in e-cigarettes can contain carcinogens      
       Correcta 1   
       Incorrect 0.073 1.72 (0.68, 4.38) 0.33 
       Don’t Know -0.052 0.74 (0.35, 1.55) 0.51 
 E-cigarettes can adversely affect lung function    
       Correcta 1   
       Incorrect 0.077 1.92 (0.61, 5.99) 0.34 
       Don’t Know -0.021 0.88 (0.41, 1.89) 0.79 
Physicians’ Demographics and Clinical Training      
 Gender (Female) -0.017 0.90 (0.48, 1.68) 0.88 
 Age in years -0.097 0.97 (0.91, 1.04) 0.53 
 Years of practice 0.075 1.02 (0.95, 1.09) 0.24 
 Specialty (General Internal Medicine) 0.009 1.06 (0.55, 2.02) 0.78 
 Board-certification (Yes) 0.04 1.36 (0.59, 3.14) 0.51 
 Medical school training (United States) -0.098 0.49 (0.18, 1.31) 0.62 
Clinical practice information      
 Geographic region      
       Midwesta 1     
       North-East 0.009 1.07 (0.47, 2.43) 0.88 
       South 0.112 1.98 (0.95, 4.13) 0.12 
       West 0.11 2.13 (0.89, 5.06) 0.14 
 Number of patients/week 0.066 1.00 (0.99, 1.01) 0.38 
 Time providing care to adult patientsb  -0.003 0.99 (0.72, 1.35) 0.96 
 Practice Sizeb -0.034 0.88 (0.57, 1.35) 0.64 
 Academic Affiliation (Yes) -0.103 0.53 (0.27, 1.03) 0.11 
Tobacco use counseling characteristics      
 Trained in smoking cessation counseling (Yes) 0.021 1.14 (0.63, 2.05) 0.71 
 Confidence in ability for tobacco use counseling in general -0.043 0.89 (0.70, 1.13) 0.43 
 Confidence in ability for e-cigarette use counseling 0.079 1.12 (0.94, 1.34) 0.25 
*Significant p-value (all bolded) 
a Reference Group 
b Ordinal variables 
OR, Odds Ratio; CI, Confidence Interval; FDA, United Stated Food and Drug Administration 
DISCUSSION 
Patient-physician discussions about e-cigarettes are becoming common place in primary 
care. Consistent with that reported by others,31-33 PCPs in our sample reported being asked by 
their patients about e-cigarettes; however, they were also initiating e-cigarette-related discussions 
with their patients. Such discussions are occurring despite many PCPs expressing uncertainty or 
incorrect knowledge regarding e-cigarettes. Those recommending e-cigarettes report doing so 
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both to help their patients stop smoking and as a harm reduction strategy. While socio-
demographic, training and practice setting characteristics did not seem to be associated with a 
PCP’s likelihood of recommending e-cigarettes, their consideration of patients’ interest in trying 
e-cigarettes and beliefs about the benefits and harms associated with e-cigarette use as well as 
beliefs regarding the relative harm of e-cigarettes in comparison to other tobacco/nicotine 
products were associated with physician reports of recommending e-cigarettes to their patients 
who smoke. 
Patient–physician discussions around e-cigarettes assessed in prior studies31-33 accounted 
only for the possibility of patients inquiring about e-cigarettes, not that physicians may be 
initiating such discussions. A substantial number of PCPs reported initiating e-cigarette 
discussions with their patients, and those PCPs who did report initiating such discussions were 
also more likely to recommend e-cigarette use to their patients. Because prior studies have not 
measured physician initiation of discussions, it is not known if this is a continuation of an 
existing practice, or whether PCPs might be becoming more proactive regarding e-cigarette-
related discussions. What is known is that the majority of PCPs report both discussing and 
recommending e-cigarettes with their patients—likely at a rate higher than previously has been 
reported. 8, 30, 31  
The overall knowledge base regarding e-cigarettes that is informing PCP-patient e-
cigarette discussions and recommendations is highly variable. Although, the FDA regulatory 
status has been long communicated via their website,36, 108 scientific journals,59, 60 the lay press 
113, and on some e-cigarette industry websites, 114, 115 one third of PCPs nationwide were still not 
aware that the FDA does not currently regulate e-cigarettes. Also, PCPs were unaware that e-
cigarettes can contain carcinogens or could adversely affect lung function. Such findings imply 
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that facts contained in recent position statements published by US medical organizations may not 
be reaching PCPs.59, 60 Furthermore, the clear void in knowledge regarding the potential harms 
associated with e-cigarettes may be indicative of the influence that industry marketing may be 
having, as such marketing tends to focus solely on the potential benefits of e-cigarettes and is 
void of any risk communication or transparent product labeling.40, 41, 98, 102-104 Such an influence 
could also explain PCPs’ generally correct knowledge that some e-cigarettes can deliver more 
nicotine than that found in traditional cigarettes, as this information is also consistent with 
current industry marketing messages.19, 96, 116, 117 Since those PCPs who reported prior e-cigarette-
related discussions with their patients were more likely to have had correct e-cigarette-related 
information, patients could also potentially be a source of PCPs’ information31 or that those 
discussions might serve as a trigger for PCPs to look for e-cigarettes-related information. Thus, 
not only could industry marketing be reaching end users of e-cigarettes, but it could be also 
directly and indirectly informing PCPs knowledge.31 This is potentially important as PCPs’ 
knowledge of the potential harms associated with e-cigarettes was associated with weaker beliefs 
regarding the potential of e-cigarettes to reduce the risk of cancer. This suggests that informing 
PCPs about the potential risk of e-cigarettes could result in less recommendation of e-cigarette 
via altering their beliefs. Regardless, it seems that PCPs’ current knowledge base is both 
inadequate and not a driving factor behind PCPs’ decisions to recommend e-cigarettes to their 
patients who smoke, perhaps due to the limited evidence-based sources of information 
available.27, 28, 31 
Like prior studies,28, 31-33, 92 we found PCPs generally to have favorable beliefs regarding 
the ability of e-cigarettes to assist with both smoking cessation and harm reduction. In fact, 
beyond patients’ interest in trying e-cigarettes, only these favorable beliefs towards e-cigarettes 
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distinguished recommenders from non-recommenders. Our results clearly illustrate that PCPs are 
recommending e-cigarettes to their patients who smoke for both harm reduction and smoking 
cessation. Since these beliefs are likely informed by industry marketing109 and not evidence-
based information, it seems highly plausible that physician recommendations to use e-cigarettes 
will continue to grow in absence of empirical evidence, and their belief that little evidence 
exists,109 may even hinder their  active looking for e-cigarette-related information.118, 119 
Our prior qualitative assessment109 suggested that patients’ interest in using  e-cigarettes 
was a key factor associated with PCPs’ recommendation of e-cigarette use. Results here further 
support this finding. PCPs appear to be adopting a patient-centered approach when 
recommending e-cigarettes in that they take the patient’s interest in trying e-cigarettes into 
account. As a patient’s involvement in a recommendation generally translates to a higher 
likelihood of adherence, 120 it is likely that many such recommendations are translating into e-
cigarette use. Future studies are needed to assess the impact of PCPs’ recommendations on e-
cigarette use initiation and smoking cessation/continued nicotine dependence. 
Limitations  
The response rate, while low, was comparable to other physicians’ surveys,121 including 
those recently published on e-cigarettes31-33 and reflective of well-documented declining PCP 
responses to mailed surveys.121 Nevertheless, there is a potential for response bias that limits the 
generalizability beyond the study sample. Respondents and non-respondents could have differed 
in un-measured ways such as their interest in the topic122 or exposure to e-cigarettes discussions 
with patients. After weighting, our sample respondents, however, mirrored those in the AMA 
Masterfile. Nevertheless, caution should be taken when generalizing results to the national 
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population of PCPs since the AMA sample is updated on voluntary basis and PCPs’ related 
information might not be up-to-date. 
Furthermore, e-cigarette products are diverse and our study did not include examination 
of PCPs’ beliefs regarding different e-cigarette types, if any. Likewise, although our survey 
content, and thus findings, were informed via in-depth interviews with practicing PCPs,109 there 
may be other important unmeasured factors associated with PCPs’ e-cigarette recommendations. 
CONCLUSION 
Discussions regarding and physician recommendations for e-cigarette use are now 
commonplace among primary care office visits.  This new norm has occurred despite limited 
evidence regarding the potential harms and benefits of e-cigarettes, and despite PCPs 
acknowledging their knowledge limitations. Our results illustrate both the importance of rapidly 
fostering the development of this knowledge base as well as an opportunity to disseminate what 
is currently known to PCPs. Whether altering this knowledge will impact PCPs’ 
recommendations for e-cigarettes is not known. What is well known, however, is that once 
physicians’ practice is established it is difficult to change,99, 123 and currently PCPs in the US—
the frontline for preventive care and tobacco use counseling—are establishing their e-cigarette 
practices mostly in absence of knowledge of either the potential harms or benefits of e-cigarette. 
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Chapter 4: Factors Associated with Primary Care Physicians’ Intention to 
Recommend E-cigarette Use to their Adult Patients Who Smoke 
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ABSTRACT 
Background:  E-cigarette use has been increasing in the United States over the past few years. 
Physicians are currently recommending the use of e-cigarettes to their patients for smoking 
cessation and harm reduction. Objective: Assess and compare the factors influencing PCPs’ 
intent to recommend e-cigarette use for patients with different tobacco use profiles. Methods: 
Using a modified Dillman approach, we administered a mailed survey to a national random 
sample (N=1430) of office-based primary care physicians (PCPs) between February and May, 
2015. Survey content and our conceptual model were informed by existing literature and 
qualitative research. Paired t-tests were used to compare PCPs’ recommendation intention for 
different patient types. M-Plus with full information likelihood estimation was used to test our 
conceptual model, and to identify the factors associated with PCPs’ intentions of recommending 
e-cigarette use to patients with different tobacco use profiles. Results: We had a 24% response 
rate. The overall mean physician recommendation intention was 16.7 (± 9.5, range= 5 to 35). 
Intentions were highest for smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1), 
followed by heavy smokers wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit 
(mean=3.50, ±2.2). The mean for PCPs’ recommendation intentions was 3.04 (±2.0) for light 
smokers wanting to quit, and 3.01 (±1.9) for light smokers refusing to quit.  The main predictor 
variables in our conceptual model were all significantly associated with PCPs’ intentions in 
addition to PCPs’ knowledge (R2=0.54, p<.001). PCPs intentions were varied by patient type. 
Limitations: There is a potential for response bias which limits the ability to generalize beyond 
the sample. Conclusion: PCPs’ intent to recommend e-cigarettes to their adult patients who 
smoke is strongly influenced by PCPs’ beliefs as well as PCPs’ consideration of patients’ interest 
in using e-cigarettes and their tobacco use profile. This recommendations’ personalization is 
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consistent with patient centered care. The impact of PCPs’ practice is not ascertained; however, 
it could potentially have negative consequences on the health of their patients unless e-cigarettes 
turn out to be an effective cessation aid and/or harm reduction strategy. Future research should 
examine e-cigarettes harms and benefits regarding different tobacco use profiles to accommodate 
PCPs’ perceptions and practice setting challenges. 
Abbreviations 
US   United States 
PCP  Primary Care Physician 
TRA  Theory of Reasoned Action 
AMA  American Medical Association 
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INTRODUCTION 
E-cigarette use has been increasing steadily in the United States (US) over the past few 
years.24 Evidence regarding the potential of e-cigarettes for smoking cessation is inconclusive 
and their role as a harm reduction strategy is still unknown.29, 45, 46, 54, 59, 60 Nevertheless, a recent 
national survey of primary care physicians (PCPs) in the US revealed that more than half of 
PCPs are recommending e-cigarettes to their adult patients who smoke.124 The same study found 
that PCPs generally believe e-cigarettes could help with smoking cessation and perceive e-
cigarettes as less harmful than other tobacco products.124  
Early studies found that physicians’ beliefs regarding the ability of e-cigarettes to 
decrease cancer risk for patients, being younger,32 or being a male physician33 were all factors 
associated with physicians’ recommendations for e-cigarette use.31-33 We recently reported 
similar findings among a national sample of PCPs.124 That study also found that PCPs report 
considering their patients’ expressed interest in trying e-cigarettes and the perceived relative 
harm reduction potential of e-cigarettes when recommending their use to patients who smoke.124 
Likewise, findings from our own qualitative study suggested that physicians may be considering 
their patients’ tobacco use profile when deciding whether to recommend e-cigarette use.109 
Despite this prior research, our understanding of the factors influencing PCPs’ e-cigarette use 
recommendations remains in its infancy, and to date has not been grounded within an established 
theoretical framework. Identifying theory-based and modifiable factors associated with PCPs’ 
recommendations for e-cigarettes could provide a critical knowledge base to our understanding 
of how e-cigarettes are being integrated within clinical practice, and thus enable tobacco control 
efforts to be well-poised to impact e-cigarette recommendation behaviors regardless of the 
direction in which they may need to be modified pending emerging evidence.125  
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Although previous studies have established that the Theory of Reasoned Action (TRA) 
provides a useful framework for explaining variability in physician intentions to recommend 
treatments to patients, 89, 126-128 to our knowledge no prior study has identified the factors 
influencing PCPs’ intent to recommend e-cigarette use to their patients who smoke, or how such 
factors may vary across patients with different tobacco use profiles. We address these knowledge 
voids by testing the appropriateness of a TRA-informed conceptual model for understanding 
PCPs’ intentions to recommend e-cigarette use to their patients who smoke.109, 124 Additionally, 
we compare and contrast the factors influencing PCPs’ intent to recommend e-cigarette use for 
patients with different tobacco use profiles (i.e. different patient types). 
Theory of Reasoned Action Informed Conceptual Model  
The TRA129 suggests that attitudes and subjective norms contribute to PCPs’ intentions to 
recommend e-cigarettes to their patients who smoke. PCPs’ intentions subsequently shape their 
decision as to whether or not to recommend e-cigarettes.87, 130 For TRA testing, attitudes and 
subjective norms items are developed via semi-structured interviews. Overall attitudes and 
subjective norms measures are created via utilizing the item total scores to account for the 
strength of the attitudes and subjective norms held by the person, and the individual items help 
understand the different factors driving attitudes and subjective norms to be able to plan effective 
TRA-based behavioral interventions.87, 89, 90 
The Model of Clinical Decision Making proposes that patient interest in using a specific 
treatment have a greater impact on physicians’ decision making when treating a chronic 
condition that is not immediately life threatening.91 Given the push to deliver patient-centered 
care and the expectation that patient interests play a role in clinician recommendations,91, 131 we 
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adapted the TRA to explicitly account for PCPs’ consideration of patients’ interest in trying e-
cigarettes. Finally, results from our prior research suggested that a PCP’s overall relative harm 
reduction perception of e-cigarettes compared to other tobacco products is likely a salient factor 
in their decision to recommend e-cigarette use.124   
The overall purpose of this study is to test the theoretical tenets of the resulting 
conceptual model (Figure 3). To accomplish that, we address two specific research objectives. 
First, we test the utility of the TRA in predicting PCPs’ overall intentions to recommend e-
cigarettes in the expanded TRA-informed conceptual model (adding patient interest and relative 
harm reduction to the model) using the total TRA item scores (Objective 1). Upon verifying the 
expanded conceptual model, we test the association of all independent variables from our 
conceptual model, including the individual items forming the PCPs’ attitudes and subjective 
norms, with PCPs’ intentions to recommend e-cigarettes for each patient type and compare 
differences in the associations identified (Objective 2).  
 
 
 
 
 
 
 
 
 
 
Figure 3: Model of Physician Intention of E-cigarette use Recommendation
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METHODS 
Participants and Data Collection 
Using the American Medical Association (AMA) Masterfile, we invited a nationally 
representative random sample of N=1,430 general internal medicine, family medicine and 
general practice physicians to complete a mailed survey. We used a modified Dillman approach 
to administer the survey.111 Physicians received up to two reminders to participate in the study 
and received a $10 gift card to a retailer of their choice as a token of appreciation upon returning 
the survey. There was no difference between responders and the national AMA pool of 
physicians except for the distribution of family medicine and general internal medicine 
specialties. Additional information regarding the sample, and survey administration process are 
reported elsewhere.124 All aspects of the study were approved by the Institutional Review Board 
of the Virginia Commonwealth University.  
Questionnaire Development 
As previously reported,109 and recommended for constructing TRA-based questionnaire 
items,89, 129, 132, 133 we used qualitative semi-structured interviews to elicit salient PCP beliefs 
regarding the outcomes associated with, facilitators of, and barriers to recommending e-
cigarettes to patients who smoke. We also used semi-structured cognitive interviews with 10 
PCPs practicing in an academic medical center to pre-test the final survey instrument for clarity 
and ease of understanding. Regardless of the wording of the TRA measures’ items, all were 
scored in such a way that higher scores represented positive responses toward the intended 
behavior (i.e. intent to recommend e-cigarettes to patients who smoke). 87  
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For the study’s intention measure, we assessed PCPs’ behavioral self-prediction of 
recommending e-cigarettes to different patient types. When measuring clinical practice 
recommendation intentions, measuring a physician’s likelihood (i.e. behavioral self-prediction) 
of performing the simulated behaviors is known to be a better proxy measure of the behavioral 
performance than measuring a physician’s desire towards the overall behavior (i.e. 
recommending e-cigarettes in general).90, 134, 135 Measuring intention in such way mimics a “real-
life” behavioral situation that more closely approximates complex clinical decisions.90, 134, 135 For 
the attitudes and subjective norms, based on cognitive testing of the final survey instrument, their 
items were only represented by their belief components and not the evaluative components to 
minimize survey burden. Adding the evaluative component for an item when the corresponding 
belief component has obviously a positive or negative outcome could be a source of 
annoyance,136 which was confirmed via our cognitive interviews. Additionally, prior studies have 
found that using the evaluative components added little variance to TRA measures.137, 138  
Measures  
E-cigarette use recommendation intention 
The PCPs’ likelihood of recommending e-cigarettes over the next three months was 
ascertained using 7-point Likert scales (Not at All Likely to Very Likely). Based on results from 
semi-structured interviews,109 we assessed likelihood for five different patient types: heavy 
smokers refusing to quit, heavy smokers wanting to quit, light smokers refusing to quit, light 
smokers wanting to quit, and smokers with prior unsuccessful quit attempts. A total intention 
score was computed by summing responses across each of the five patient types (Cronbach α 
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=0.94). The overall summed score was used for Objective 1. The intention score for each patient 
type was used for Objective 2. 
Attitudes 
We measured attitudes using four items with a 7-point Likert bipolar response scale. 
PCPs were invited to indicate the likelihood (Very Unlikely to Very Likely) of their patients’ use 
of e-cigarettes resulting in the following: ‘help patients quit smoking,’ ‘decrease their cancer 
risk,’ and ‘limit secondhand smoke exposure to patients’ families and friends’ as well as their 
agreement (Strongly Agree to Strongly Disagree) with ‘e-cigarette use can create dual tobacco 
users.’ A total overall attitude score was computed (Cronbach α=0.84) and used for Objective 1. 
The four individual items were used for Objective 2. 
Subjective norms  
We measured subjective norms using four items with a 7-point Likert bipolar response 
scale. We asked PCPs to indicate whether the following groups would disapprove or approve of 
their e-cigarette recommendation: ‘specialty physicians to whom I refer my patients,’ ‘the 
professional societies to which I belong,’ ‘my primary care physician colleagues,’ and ‘my 
patients who smoke.’ A total subjective norm score was computed (Cronbach α =0.71) and used 
for Objective 1. The four individual items were used for Objective 2. 
Patients’ interest in trying e-cigarettes 
We assessed PCPs’ consideration of their patients’ interest in trying e-cigarettes by 
asking whether patient’s interest is/would be a primary reason for recommending e-cigarettes.  
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Responses were presented on a 7-point Likert scale (Strongly Disagree to Strongly Agree) and 
used in all analyses.  
Relative harm reduction 
To compute an e-cigarette relative harm reduction perception measure we asked 
physicians to rate how harmful e-cigarettes and five other tobacco products are to the health of 
their patients using a 7-point Likert scale (Not at All Harmful to Extremely Harmful). Tobacco 
products considered were traditional cigarettes; tobacco pipes; waterpipes [hookah or narghile]; 
cigars, cigarillos and little cigars; and smokeless tobacco. We constructed five relative harm 
reduction items by subtracting the e-cigarette score from each of the other tobacco product 
scores. A total relative harm reduction score was produced by summing the five constructed 
items (Cronbach α =0.93). The resulting overall harm reduction score was used in all analyses 
with positive scores indicating relatively less harm from e-cigarettes. 
Knowledge and other control variables  
When testing associations, we controlled for a number of other PCP characteristics, 
including e-cigarette knowledge. A knowledge score (range 0-5) was constructed by summing 
the number of correct responses the PCP gave to five true/false knowledge questions. These 
questions were based on the current literature and expert opinion, 124 and included items such as 
‘the nicotine liquid used in e-cigarettes can contain carcinogens’ and ‘some e-cigarettes can 
deliver more nicotine than traditional cigarette.’ We also collected information on year of birth 
(for age computation), gender, years of clinical experience post training completion, and average 
number of patients seen per week.   
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Statistical Analysis 
Descriptive statistics were used to characterize the sample and intentions of PCPs to 
recommend e-cigarettes. We used paired sample t-tests to compare mean PCP recommendation 
intention scores by patient types. Although item non-response did not exceed 3.3%, we 
nevertheless used M-Plus with full information likelihood estimation for model testing in support 
of both objectives. To address Objective 1, we tested a path model reflecting the full conceptual 
model (i.e., inclusive of patient interest and relative harm reduction). To address Objective 2, we 
used a multivariate, multivariable regression model to simultaneously compare and contrast the 
model components associated with physician intention to recommend e-cigarette use to different 
patient types. For all analyses, we used post-stratification weights to account for the 
disproportionate survey response rate between family physicians and general internal medicine 
physicians.124 In all models, we report the standardized estimates of the beta coefficients, and 
their p-values as well as the adjusted R2. Variables were considered statistically significant at 
p<0.05. 
RESULTS 
Sample Characteristics 
Data from a total of 274 participants were used in the analysis. The survey response rate 
adjusted for ineligible cases was 24%.112 The majority of respondents were males (63%).  Mean 
years of practice was 19.6 (+11.2), mean age was 52.2 (+10.7) years, mean number of patients 
seen per week was 81.3 (+35.5), and the mean knowledge score was 2.3 (+1.5) of a possible 5 
points. The mean overall total score for the relative e-cigarette harm reduction perception was 
8.6 (+9.0, range= -5 to 30) reflecting a perception that e-cigarettes were relatively less harmful 
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than other tobacco products. PCPs generally agreed that patient interest in trying e-cigarette 
would influence their recommendation decisions (mean=4.1, ±1.8, range 1 to 7). The mean 
attitude and subjective norms scores are presented in Table 6. 
Table 6: Mean Attitude and Subjective Norm Scores: Individual Items and Overall 
(N=274) 
Measures Mean (SD) 
Cronbach’s 
alpha 
Individual attitude items (range: -3 to +3)   
Help quit smoking -0.04 (±1.6)  
Limit second-hand smoke exposure  1.39 (±1.6)  
Decrease cancer risk 0.24 (±1.6)  
Create dual tobacco users (reverse scored) -0.82(±1.4)  
Total Attitudes (range -12 to 12) 0.77(±4.6) 0.84 
Individual subjective norm items (range: -3 to +3)  
Specialty physicians -0.33 (±1.2)  
                Professional societies -0.50 (±1.2)  
                Primary care physician colleagues -0.33 (±1.3)  
                Patients who smoke 0.51 (±1.2)  
Total subjective norm (range -12 to 12) -0.63(±4.1) 0.71 
 
E-cigarette Recommendation Intentions 
The overall mean physician recommendation intention was 16.7 (± 9.5, range= 5 to 35). 
Intentions were highest for smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1), 
followed by heavy smokers wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit 
(mean=3.50, ±2.2). The mean for PCPs’ recommendation intentions was 3.04 (±2.0) for light 
smokers wanting to quit, and 3.01 (±1.9) for light smokers refusing to quit. As shown in Table 7, 
mean intentions to recommend e-cigarette use for smokers with unsuccessful quit attempts was 
not significantly different than that for heavy smokers, but was significantly higher than that for 
light smokers, irrespective of the willingness to quit. Similarly, recommendation intention for 
heavy smokers was significantly higher than that for light smokers irrespective of the willingness 
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to quit. Physicians’ recommendation intentions were not differentiated by the patient’s 
willingness to quit, regardless of whether the patient was a heavy or light smoker.  
Table 7: Comparison of Physicians’ E-cigarette Recommendation Intentions for Different 
Patient Types (N=274) 
Patient Type Comparisons Mean (SD) T- Statistic P-value 
Smokers with prior unsuccessful quit attempts 3.63 (±2.1)  
0.93 0.351 
              vs. Heavy smokers wanting to quit 3.57 (±2.2) 
  
1.87 0.062 
              vs. Heavy smokers refusing to quit 3.48 (±2.2) 
  
6.76 <.001 
              vs. Light smokers wanting to quit 3.03 (±2.0) 
  
7.78 <.001 
              vs. Light smokers refusing to quit 2.99 (±1.9) 
Heavy smokers wanting to quit 3.58 (±2.2) 
0.95 0.345 
              vs. Heavy smokers refusing to quit 3.50 (±2.2) 
  
5.98 <.001 
              vs. Light smokers wanting to quit 3.04 (±2.0) 
 3.58 (±2.2) 
6.17 <.001 
              vs.  Light smokers refusing to quit 3.01 (±1.9) 
Heavy smokers refusing to quit 3.50 (±2.2) 
3.92 <.001 
             vs. Light smokers wanting to quit 3.05 (±2.0) 
  
5.47 <.001 
             vs. Light smokers refusing to quit 3.01 (±1.9) 
Light smokers wanting to quit 3.04 (±2.0) 
0.41 0.683 
             vs. Light smokers refusing to quit 3.01 (±1.9) 
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E-Cigarette Use Recommendation Intentions and the Expanded Theory of Reasoned 
Action 
Results from the path model are shown in Figure 4. The overall PCPs’ intentions to 
recommend e-cigarette use was significantly associated with the PCPs’ total attitudes and 
subjective norms, consideration of patients’ interest, e-cigarette relative harm perception and e-
cigarette knowledge (R2=0.54, p<.001). PCPs who had a more favorable attitude towards e-
cigarettes, believed more strongly in the relative harm reduction ability of e-cigarettes compared 
to other tobacco products, perceived that recommending e-cigarettes would be generally 
approved of by their salient referents, and had better e-cigarette-related knowledge were more 
likely to intend to recommend e-cigarettes to their patients who smoke. Similarly, PCPs who 
perceived their patients to be interested in trying e-cigarettes were also significantly more likely 
to intend to recommend them to their patients. Upon testing the path model indirect effects, we 
found that attitudes mediated the effect of knowledge (β=-0.049, p=0.023) and gender (β=-0.065, 
p=0.008) on intentions, relative harm reduction perception mediated the effect of knowledge 
(β=-0.052, p=0.007) and gender (β=-0.037, p=0.030) on intentions, and subjective norms 
mediated the effect of age (β=-0.082, p=0.016) and years of practice (β=0.073, p=0.025) on 
intentions. 
 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Conceptual Model Fit Utilizing Observed TRA Measures 
 
Factors associated with E-Cigarette Recommendation Intentions by Patient Types 
Results from the multivariate multivariable regression model showed that increased 
PCPs’ perception of approval by their PCP colleagues and patients who smoke (two of the social 
norm measures) were associated with their intentions to recommend e-cigarette use regardless of 
patient type. Increased belief that e-cigarettes could help patients quit smoking (an attitude 
measure) was also associated with PCPs’ intentions for all patient types. Furthermore, increased 
belief that e-cigarettes decrease cancer risk for smokers and the relative harm reduction potential 
of e-cigarettes were associated with increased intentions to recommend e-cigarettes to all patient 
types, except for light smokers wanting to quit. Consideration of the patient’s interest in using e-
cigarettes was significantly associated with physician’s intentions to recommend e-cigarettes for 
*p≤.05 
**p≤.01 
***p≤.001 
This is a saturated model. Only significant pathway coefficients are shown. 
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smokers with unsuccessful quit attempts, and for light smokers. The PCPs’ e-cigarette 
knowledge was generally not significantly associated with their recommendation intention; the 
exception was among smokers with prior unsuccessful quit attempts where knowledge was 
positively associated with recommendation intent. 
Table 8: Multivariate, Multivariable Model Results: Factors Associated with Physicians’ 
Intent to Recommend E-Cigarettes by Patient Types (N=274) 
Patient Type Explanatory Variables 
(A=Attitude), (SN=Subjective Norm) 
Standardized 
β coefficient 
P for β Model’s R 
squared 
Heavy Smoker 
Refusing to Quit 
Help Quitting (A) 0.267 <.001 
0.487* 
Decrease Cancer Risk (A) 0.163 0.011 
Primary Care Physician Colleagues (SN) 0.228 0.014 
Patients Who Smoke (SN) 0.147 0.002 
Relative Harm Reduction of E-cigarettes 0.162 0.006 
Number of Patients Seen per Week 0.131 0.003 
Heavy Smoker 
Wanting to Quit 
Help Quitting (A) 0.214 <.001 
0.562* 
Decrease Cancer Risk (A) 0.169 0.005 
Specialty Physicians (SN) -0.154 0.018 
Primary Care Physician Colleagues (SN) 0.383 <.001 
Patients Who Smoke (SN) 0.094 0.042 
Relative Harm Reduction of E-cigarettes 0.209 <.001 
Number of Patients Seen per Week 0.134 0.003 
E-cigarette Knowledge  0.142 0.001 
Light Smoker 
Wanting to Quit 
Help Quitting (A) 0.259 <.001 
0.443* 
Primary Care Physician Colleagues (SN) 0.272 0.004 
Patients Who Smoke (SN) 0.124 0.016 
Patient Interest in Using E-cigarettes 0.189 <.001 
Light Smoker 
Refusing to Quit 
Help Quitting (A) 0.205 <.001 
0.417* 
Decrease Cancer Risk (A) 0.139 0.049 
Primary Care Physician Colleagues (SN) 0.316 0.001 
Patients Who Smoke (SN) 0.148 0.006 
Patient Interest in Using E-cigarettes 0.125 0.019 
Relative Harm Reduction of E-cigarettes 0.156 0.017 
Smokers with 
Prior Unsuccessful 
Quit Attempts 
Help Quitting (A) 0.270 <.001 
0.566* 
Decrease Cancer Risk (A) 0.154 0.012 
Primary Care Physician Colleagues (SN) 0.316 0.001 
Patients Who Smoke (SN) 0.145 0.002 
Patient Interest in Using E-cigarettes 0.106 0.032 
Relative Harm Reduction of E-cigarettes 0.209 <.001 
Number of Patients Seen per Week 0.100 0.020 
E-cigarette Knowledge  0.090 0.038 
*p-value <.001 
Only Significant predictors are presented in the table. 
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Discussion 
Consistent with the assumptions laid in our  Theory of Reasoned Action informed 
conceptual model, PCPs’ intentions to recommend the use of e-cigarettes to their patients who 
smoke were largely driven by their attitudes and subjective norms.124 Additionally, PCPs’ 
consideration of patient interest in using e-cigarettes and their relative harm perceptions of e-
cigarettes were significant drivers as well. However, neither PCPs’ intentions, nor the drivers of 
those intentions were uniform across all patient types. Physicians’ intentions to recommend e-
cigarettes were particularly high among heavy smokers and those with unsuccessful quit attempts 
relative to light smokers. Similarly, physicians’ beliefs that e-cigarettes can decrease cancer risk 
for patients was significantly associated with their intentions to recommend e-cigarettes for all 
patient types except for light smokers wanting to quit. Conversely, consideration of patients’ 
interest in using e-cigarettes was associated with PCPs’ intentions to recommend e-cigarettes for 
light but not for heavy smokers.  Such findings are consistent with the finding  that e-cigarettes 
are being recommended by PCPs for harm reduction33, 124 as well as for smoking cessation, 32, 124 
but also illustrate how PCPs’ intent to recommend e-cigarettes may be highly personalized to 
specific patient contexts and situations. 
Variation in PCPs’ tobacco use counseling recommendations are well established,76, 139-
141 with PCPs being known to deliver counseling more frequently to heavy smokers.139 PCPs also 
tend to recommend higher doses of cessation pharmacotherapies or more intensive behavioral 
interventions to help heavy smokers quit.76, 140, 141 The increased intention to recommend e-
cigarettes for patients perceived to be heavy smokers or those patients who have tried to quit 
multiple times, could indicate that e-cigarette recommendations are not yet a standard approach 
to tobacco use counseling in primary care but instead one that is being used selectively. Despite 
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that fact that the morbidity linked to smoking is comparable regardless of the amount a patient 
smokes142 and that that all forms of tobacco use should be avoided completely,62 prior studies 
have continually shown PCPs behave differently when targeting “heavy” versus “light” 
smokers.76, 140, 141 Our results are no different: PCPs’ intention to recommend e-cigarettes caries 
by patient tobacco use. This could mean that e-cigarettes are being incorporated into physician 
cessation counseling in the same manner that other cessation aids are used. PCPs’ advice of 
different tobacco use counseling treatments has not always been tied to patients’ willingness to 
quit,143 which was also observed in PCPs’ recommendation intentions for e-cigarette use. It is 
possible that PCPs are incorporating e-cigarettes into their counseling in a way that is similar to 
other cessation medications, or that e-cigarettes could be regarded by PCPs as a part of an 
intensive counseling approach aiming at improving the likelihood of future cessation attempts 
among those unmotivated to quit.140 Whether e-cigarette recommendations are made after 
offering recommended evidence-based cessation therapies cannot be known without future 
studies.   
PCPs appear to be taking a patient-centered approach to e-cigarette recommendations.  
We found PCPs’ intent to recommend e-cigarettes—regardless of patient type—to be associated 
with their patients’ perceived approval. However, when it comes to PCPs’ consideration of 
patient interest in trying e-cigarettes, it was not consistently associated with their 
recommendation intention for all patient types. This association was significant for light smokers 
and those with unsuccessful quit attempts, but not for heavy smokers. This suggests that, despite 
patients being a salient referent for PCPs when making their treatment decisions, once PCPs 
perceive smokers to be of higher risk their consideration of patient interest contributes less to 
their recommendation decision as they perceive their patient status to warrant immediate 
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attention regardless of the patient’s interest.91 This in itself suggests that PCPs’ relatively high 
recommendation intention for heavy smokers, not being driven by their patients’ interest, could 
be an implicit endorsement for e-cigarettes’ harm reduction potential for heavy smokers. On the 
other hand, patients’ interest was a driver for PCPs’ intention to recommend e-cigarette use to 
light smokers. Given that patient interest is likely growing because of industry marketing,24, 27, 96 
in addition to a growing proportion of light smokers in general,144 it is very likely that PCPs’ 
intention to recommend e-cigarettes to light smokers, and hence their future recommendations,145 
could grow. The likely impact of this personalized approach by PCPs according to patient types 
could be assessed in future studies. Specifically, whether such an approach by PCPs might have 
its intended results, such as helping patients quit smoking, or possibly unintended results, such as 
creating dual tobacco users, needs to be ascertained. 
Having accurate e-cigarette knowledge was directly associated with physicians’ 
intentions to recommend e-cigarettes and was mediated by PCPs’ attitudes and relative harm 
reduction perception. This suggests that PCPs who take the time to gather information about e-
cigarettes could be developing favorable beliefs regarding e-cigarettes. Since evidence-based 
information sources continue to be limited for e-cigarettes, it is likely that physicians who seek 
information on e-cigarettes are finding industry-sponsored material.31, 124 Such material is 
currently unregulated and known to minimize what is known regarding the potential risks 
associated with e-cigarette use.30, 146 Consistent with this, our prior research has found PCPs to 
be more knowledgeable of the potential benefits of e-cigarettes relative to their potential 
harms.124 Thus, not only is research needed to assess the health and other benefits and risks 
associated with e-cigarette use, but efforts are needed to help synthesize and disseminate what 
little is known about the impact of e-cigarettes, particularly known risks.   
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Limitations 
We studied PCPs intentions to recommend e-cigarettes, which although likely associated 
with, may not translate to their e-cigarette-related recommendations. Future longitudinal studies 
are needed to test how PCPs’ intentions would affect their actual recommendation behavior. Care 
also should be taken when generalizing findings to other populations of PCPs. As is increasingly 
the case with physician surveys,121 we had a relatively low response rate, and respondents and 
non-respondents could have differed in un-measured ways such as their interest in the topic122 or 
exposure to e-cigarettes discussions with patients. Furthermore, although the sample was drawn 
from the AMA Masterfile it may not be representative of the population of PCPs practicing in 
the US. However, the response rate was comparable to other physician surveys,121 including 
those recently published on e-cigarettes31-33 and we used post-stratification weights to correct for 
the known response bias by PCP reported primary specialty. 
Furthermore, the available sample size precluded testing individual attitude and 
subjective norms items in the path model. Thus, our ability to understand the influence of 
specific beliefs and subjective norms is limited. However, the overall measures used had good 
internal consistency. Additionally, the patient types used were chosen to mimic clinical practice 
situations that PCPs commonly face. They did not, however, fully account for the complex 
situations that PCPs could encounter during e-cigarettes related discussions, and thus may have 
missed important clinical considerations. Likewise, e-cigarette products are diverse and our 
study did not include examination of PCPs’ beliefs regarding different e-cigarette types, if any. 
Furthermore, although our survey content, and thus findings, were informed via in-depth 
interviews with practicing PCPs,109 there may be other important unmeasured factors associated 
with PCPs’ e-cigarette recommendations. 
 
 
71 
 
CONCLUSION 
PCPs’ intent to recommend e-cigarettes to their adult patients who smoke is strongly 
influenced by their beliefs regarding e-cigarettes, particularly the potential for harm reduction 
relative to other tobacco products, and by the social norms influenced by their primary care 
colleagues and patients. Consistent with such influential factors, PCPs’ intent to recommend e-
cigarettes is not uniform across patient types. Instead, PCPs’ are considering specific patient 
scenarios characterized by both the amount a patient smokes and their prior failed quit attempts. 
While such personalization is consistent with patient centered care, and because PCPs’ intentions 
are likely to translate to future recommendations,145, 147 this may help sustain nicotine dependence 
or create dual use, among primary care patients that could have otherwise quit completely using 
pharmacotherapies that are approved by the US Food and Drug Administration. This may also 
cause unknown harms to patients, many of which are potentially heavy smokers already heavily 
exposed to known smoking harms, unless e-cigarettes are ultimately identified as an effective 
harm reduction strategy. Finally, the e-cigarette related research agenda should examine e-
cigarettes harms and benefits regarding different patient types to account for PCPs perceptions 
and real practice setting challenges. 
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Chapter 5: Conclusions 
 
The three studies presented in this dissertation build upon each other. My qualitative 
assessment of Primary Care Physicians (PCPs) beliefs and practices regarding the use of e-
cigarettes by patients who smoke provided the first in-depth study of PCPs’ beliefs and 
recommendations pertaining to e-cigarettes. Until now, published literature assessing PCPs’ 
practices regarding e-cigarettes31-33 has not been informed by a formative step. By stepping back 
and conducting this formative research, I was able to gain valuable insights into the dynamics 
that occur between PCPs and patients in clinical practice. My formative research yielded several 
important results that in turn guided the instrument development, conceptual model, and methods 
used in my quantitative research. First, the results provided a provisional understanding of the 
attention that PCPs give to e-cigarettes in their routine tobacco use counseling and how the 
communication regarding these products tends to occur. They also highlighted the fact that e-
cigarettes are recommended for both smoking cessation and harm reduction that some PCPs are 
proactively raising the topic of e-cigarettes with their patients who smoke, and the general lack 
of a knowledge base about e-cigarettes held by most PCPs. There were two important points that 
were clear from the interviews: PCPs believe that e-cigarettes are a safer alternative to smoking 
combustible tobacco products, and although they did not typically seem to be recommending e-
cigarette use to their patients, their concerns regarding the potential harms of e-cigarettes are 
abandoned in highly addicted patients and those with extensive comorbidities. In other words, 
PCPs’ decision to recommend e-cigarettes seemed to be influenced by their patients’ tobacco use 
profile and PCPs’ perceived level of addiction of those patients. 
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Another important finding was that at least some PCPs seemed to consider their patients’ 
interest in trying e-cigarettes, suggesting that PCPs adopting a patient centered approach could 
be incorporating e-cigarettes into their clinical practice. Nevertheless, these findings were drawn 
from a small sample of PCPs practicing in two settings in Virginia. Thus, there was a need to test 
the different assumptions and findings in a larger and more diverse sample of PCPs. 
Building on these findings, the aims of my second study were to estimate the prevalence 
of PCPs who recommend e-cigarettes to their patients as a smoking cessation aid or as a harm 
reduction strategy and to identify PCPs’ beliefs, e-cigarette-related knowledge, and other factors 
associated with their recommending e-cigarettes to their adult patients who smoke. Through 
mailed surveys to a national sample of office-based PCPs, these aims were addressed. Findings 
from this study indicated that PCPs’ recommendations of e-cigarettes have become 
commonplace in primary care practice settings for smoking cessation as well as for harm 
reduction. Furthermore, results from my survey confirmed that PCPs are not only being asked by 
their patients about e-cigarettes, as previous studies have indicated, 31-33 but also that PCPs 
themselves are initiating such discussions and those who reported initiating discussions were 
more likely to recommend e-cigarettes which reflects that there could be some PCPs who 
actively advocate for e-cigarette use. PCPs’ recommendations of e-cigarettes to their adult 
patients who smoke were mainly associated with having favorable beliefs towards e-cigarettes’ 
ability to help patients quit smoking, be exposed to less harm than as from other tobacco 
products, and reduce second hand smoke exposure to other people. Those PCPs seemed to decide 
intuitively rather than factually, given their lack of correct information, which is a common 
decision-making process in cases of uncertainty.148 PCPs who reported recommending e-
cigarettes were also more likely to take patients’ interest in using e-cigarettes in consideration. 
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However, PCPs -regardless of whether or not they recommended e-cigarettes to their patients 
who smoke- had limited knowledge about the features and potential harms of e-cigarettes, and 
often did not know that e-cigarettes are not regulated by the United States Food and Drug 
Administration. Collectively, this could mean that PCPs are being influenced by industry 
marketing rather than relying on the limited evidence-based sources available regarding e-
cigarettes. Results from this study, therefore, highlighted the need to disseminate the existing 
knowledge regarding the potential harms and benefits of e-cigarettes to PCPs so that they can 
accurately discuss e-cigarettes with their patients. Without such knowledge, neither physicians 
nor patients can make informed decisions regarding e-cigarette use.   
In my last study, I used a conceptual model that was informed by the Theory of Reasoned 
Action (TRA); which proposes that physicians’ behavioral intent, in this case the intention to 
recommend e-cigarettes to their patients who smoke, is determined by both attitudes and 
subjective norms. I supplemented these TRA domains with the domain of patient interest from 
the Model of Medical Decision Making and findings from my formative research to predict 
PCPs’ intentions to recommend e-cigarettes. This was done using the same physician sample and 
cross-sectional survey employed in my second paper. It is important to note that patient interest 
in treatment was significant in all of the analysis I performed throughout the dissertation. This 
finding illustrates the likely influence of patient preferences in the context e-cigarettes,148 and the 
need to better understand how patient beliefs and preferences regarding e-cigarettes are being 
formed.  
Of interest here were not only the factors that drive physicians overall intent to 
recommend e-cigarettes, but whether the intent and the factors behind that intent may vary across 
different types of patients. The types of patients considered were classified based on nicotine 
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dependence levels (heavy versus light smokers), willingness to quit, and prior quit attempts. 
Each of these was identified as a potentially important tobacco use attribute in my formative 
research. 
The overall PCPs’ intentions to recommend e-cigarette use was significantly associated 
with the PCPs’ total attitudes and subjective norms, consideration of patients’ interest, e-cigarette 
relative harm perception and e-cigarette knowledge. However, PCPs’ propensity to intend to 
recommend e-cigarettes to their patients varied by patient type, as well as the factors fuelling 
those intentions. PCPs’ perception of e-cigarettes potential to decrease patients’ cancer risk, as 
well as consideration of patients’ interest in trying e-cigarettes differentiated the five patient 
types I included in the study. On the other hand, PCPs’ belief that e-cigarettes can help patients 
quit smoking was associated with all patient types. While such personalization is consistent with 
patient centered care, there could also be unintended consequences like potentially initiating dual 
use or sustaining nicotine addiction in patients who are already heavily dependent on nicotine. 
Moreover, this variability in recommendation intention by patient type mimics PCPs’ practice 
with conventional smoking cessation aids. Despite the fact that being a light smoker does not 
carry substantially less risk compared to being a heavy smoker,62 PCPs seem to perceive the risk 
to be different, and act accordingly. For example, in my qualitative interviews in phase one, a 
PCP mentioned that “ The people who are smoking like a pack a day and really chimneys, I’m 
like you want anything that you can do that’s an action that gets in the right direction.  So I 
usually am pretty encouraging of it in that setting”109. This highlights the perception that 
smoking more cigarettes is more harmful than smoking fewer cigarettes per day and therefore 
warrants a need to recommend anything including e-cigarettes for this particular population. 
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Taken together, findings from these three studies have important implications for both 
research and practice. Of particular note is the general lack of what limited factual information 
there is regarding e-cigarettes among PCPs. There is a need for comprehensive mapping of 
PCPs’ sources of information, as well as their preferred channels of communication, in order to 
know how to effectively disseminate e-cigarette information to PCPs. Differences in nicotine 
delivery and other features of e-cigarettes might pose complexity for physicians’ information 
gathering, and eventually their decision making. As was noted in the second study, the 
assessment of the actual impact of a PCP’s recommendation to a patient to use e-cigarettes has 
yet to be explored. This seems important as it has been suggested that physician-patient 
communication regarding e-cigarettes might be shaping patients’ perception and their decision to 
use e-cigarettes.33  
My findings also indicated a need for more in-depth research regarding how PCPs are 
incorporating e-cigarette recommendations in clinical practice. While results from my 
dissertation research indicated clearly that physicians are advocating for the use of e-cigarettes 
for some patients, my research was unable to determine whether such recommendations are 
being made as first line therapies for particular types of patients or only after other evidence-
based therapies have been exhausted. Additionally, I was unable to ascertain whether there are 
specific subgroups of patients with whom PCPs are more likely to introduce the idea of trying e-
cigarettes. Likewise, we have a limited understanding of the dynamics and conversational 
context of patient-physician e-cigarette discussions and how those may impact physician 
recommendations or patient adherence to those recommendations. PCPs appear to be applying 
their usual counseling techniques regarding e-cigarettes, which are routine and familiar. This 
approach could misguide patients’ use of such products or render current tobacco use counseling 
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ineffective. Finally, there is a need for further studies to better understand the risk and benefit 
profile of e-cigarettes in order to inform PCPs and patients alike. 
Despite the efforts of some US cities to regulate e-cigarettes use and marketing, there are 
no approved or pending regulatory actions as of yet on a country level in the US. Other countries 
have taken drastic measures to limit e-cigarette advertising and vaping in public. For example, 
the European parliament issued a ban on e-cigarette advertising that is scheduled to go into effect 
in the 28 European union countries in 2016.49 PCPs in the US are well positioned to serve as 
strong advocates and partners with public health organizations like the American Lung 
Association to lobby for quick and strict measures that could eventually limit the exponential 
spread of e-cigarette use among smokers and non-smokers. Taking such early stance is important 
given that active, or passive, approval of e-cigarettes by PCPs could help spread e-cigarette use 
as was the case with conventional cigarettes in the forties and fifties. 149 The current silence from 
the regulatory US-authorities, approval of and recommendation by some physicians and the 
widespread advertising and marketing of e-cigarettes could be misperceived by the public as a 
proof of e-cigarette safety. In fact e-cigarette diffusion mimics that of dietary supplements where 
despite the lack of rigorous empirical evidence or FDA regulation150 products are heavily 
marketed,151 and PCPs recommend them to their patients.152 The result has been continued use of 
these products among US consumers. 151 
My results also have immediate practice implications which could be addressed while the 
evidence base surrounding the impact of e-cigarettes on patient health and other outcomes 
continues to evolve. Collectively, my results pointed to a clear lack of knowledge regarding e-
cigarettes among PCPs.  In particular, there appears to be a void in knowledge regarding known 
potential risks and harms associated with e-cigarette use. Existing position statements of clinical 
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care organizations in the United States, while silent on many factors pertaining to e-cigarettes, all 
advocate for clinicians to discuss available albeit limited evidence with their patients. If 
clinicians are not informed of what is currently known regarding both the potential benefits and 
harms associated with e-cigarettes, they cannot be in a position to have such conversations and 
thus to support their own and their patients’ informed decision making. Such information needs 
to be communicated efficiently on a continual basis given the rapidly evolving evidence base. 
Additional efforts are needed to correctly inform the public about e-cigarettes to help them make 
an informed decision about its use and because it seemed that their perceptions are also shaping 
PCPs’ perceptions and decisions. 
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Appendix 1: Semi-structured Interviews Consent Form 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
TITLE: Impact of E-cigarettes on Physician Recommendations of Tobacco Use Cessation 
Pharmacotherapy in Primary Care 
VCU IRB NO.: HM20000547 
If any information contained in this consent form is not clear, please ask the study staff to 
explain any information that you do not fully understand. You may take home an unsigned copy 
of this consent form to think about or discuss with family or friends before making your 
decision. 
PURPOSE OF THE STUDY  
The purpose of this research study is to find out about physicians attitudes and practice 
pertaining to tobacco use cessation counseling in primary care practice. You are being asked to 
participate in this study because you are a primary care physician. 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will be asked to sign this consent form after you 
have had all your questions answered and understand what will happen to you. 
In this study you will be asked to complete one in-person interview.  The interview will last 
about 45 minutes to 1 hour.  In the interview you will be asked about your practice regarding 
tobacco use cessation counseling recommendations and your perspective about cessation aids.   
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The interview will be audio recorded so we are sure to get all the information.  The audio 
recording will not be shared with others and no names will be recorded on the tape. 
Significant new findings developed during the course of the research which may relate to your 
willingness to continue participation will be provided to you. 
RISKS AND DISCOMFORTS 
We do not expect that you will experience any risks or discomforts by participating.  If there are 
any questions that make you uncomfortable or that you do not want to talk about, you do not 
have to answer.  You may decide to discontinue the interviews at any time. If you become upset, 
the study staff will give you names of counselors to contact so you can get help in dealing with 
these issues. 
BENEFITS TO YOU AND OTHERS 
You may not get any direct benefit from this study, but, the information we learn from 
participants in this study may help to improve tobacco use cessation counseling for patients and 
physicians in the future. 
COSTS 
There are no costs for participating in this study other than the time you will spend being 
interviewed. 
PAYMENT FOR PARTICIPATION 
You will receive a $35 gift card as a thank you for your participation in the interview. 
ALTERNATIVES 
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Taking part in this research study is voluntary. Instead of being in this research study, you have 
the following option: 
• Decide not to participate in this research study 
CONFIDENTIALITY 
Your confidentiality is very important to us.  Potentially identifiable information about you will 
consist of audio recordings and transcriptions of interviews. Data is being collected for research 
purposes only.  Your data will be identified by ID numbers, not names, and stored separately 
from medical records in a locked research area. All study related documents and audio tapes will 
be stored in a secure location until the study has ended and all data analyses is complete.  At that 
time, all study material will be placed in a secured long term storage facility until it is deemed 
appropriate to destroy the study material. 
The results of this research study may be presented at meetings or published, but your name will 
not ever be used in these presentations or papers. 
We will not tell anyone the answers you give us; however, the consent form signed by you may 
be looked at or copied for research or legal purposes by Virginia Commonwealth University.   
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
You do not have to participate in this study. If you choose to participate, you may stop at any 
time without any penalty. You may also choose not to answer particular questions that are asked 
in the study. 
Your participation in this study may be stopped at any time by the study staff without your 
consent. The reasons might include: 
 the study staff thinks it necessary for your health or safety; 
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 you have not followed study instructions; or 
 administrative reasons require your withdrawal. 
If you are removed from the research study, the research Investigator will explain to you why 
you were removed 
QUESTIONS 
If you have any questions, complaints, or concerns about your participation in this research, 
contact: 
Omar El Shahawy, MBBCh, MPH (804) 628-2997 or  
Jennifer Elston Lafata, PhD (804) 628-3293 
 
The researcher and study staff named above are the best persons to call for questions about your 
participation in this study.  
If you have any general questions about your rights as a participant in this or any other research, 
you may contact: 
 Office of Research 
 Virginia Commonwealth University 
 800 East Leigh Street, Suite 3000 
 P.O. Box 980568 
 Richmond, VA  23298 
 Telephone: (804) 827-2157 
Contact this number for general questions, concerns or complaints about research. You may also 
call this number if you cannot reach the research team or if you wish to talk with someone else.  
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General information about participation in research studies can also be found at 
http://www.research.vcu.edu/irb/volunteers.htm. 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says that 
I am willing to participate in this study.  I will receive a copy of the consent form once I have 
agreed to participate. 
 Participant name printed   Participant signature  Date 
 
________________________________________________ 
Name of Person Conducting Informed Consent  
Discussion / Witness   
(Printed) 
________________________________________________ ________________ 
Signature of Person Conducting Informed Consent   Date 
Discussion / Witness  
 
________________________________________________ ________________ 
Principal Investigator Signature (if different from above)   Date  
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Appendix 2: Cognitive Interviews Consent Form 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
TITLE: Impact of E-cigarettes on Physician Recommendations of Tobacco Use Cessation 
Pharmacotherapy in Primary Care 
VCU IRB NO.: HM20000547 
SPONSOR: American Lung Association 
If any information contained in this consent form is not clear, please ask the study staff to 
explain any information that you do not fully understand. You may take home an unsigned copy 
of this consent form to think about or discuss with family or friends before making your 
decision. 
PURPOSE OF THE STUDY  
The purpose of this research study is to find out about physicians attitudes and practice 
pertaining to tobacco use cessation counseling in primary care practice. You are being asked to 
participate in this study because you are a primary care physician. 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will be asked to sign this consent form after you 
have had all your questions answered and understand what will happen to you. 
In this study you will be asked to complete one in-person interview.  The interview will last 
about 45 minutes to 1 hour.  In the interview you will be asked about your understanding of a 
series of questions and their relevance regarding tobacco use cessation counseling 
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recommendations and how these questions capture your prespective pertaining to cessation aids.   
The interview will be audio recorded so we are sure to get all the information.  The audio 
recording will not be shared with others and no names will be recorded on the tape. 
Significant new findings developed during the course of the research which may relate to your 
willingness to continue participation will be provided to you. 
RISKS AND DISCOMFORTS 
We do not expect that you will experience any risks or discomforts by participating.  If there are 
any questions that make you uncomfortable or that you do not want to talk about, you do not 
have to answer.  You may decide to discontinue the interviews at any time. If you become upset, 
the study staff will give you names of counselors to contact so you can get help in dealing with 
these issues. 
BENEFITS TO YOU AND OTHERS 
You may not get any direct benefit from this study, but, the information we learn from 
participants in this study may help to improve tobacco use cessation counseling for patients and 
physicians in the future. 
COSTS 
There are no costs for participating in this study other than the time you will spend being 
interviewed. 
PAYMENT FOR PARTICIPATION 
You will receive a $35 gift card as a thank you for your participation in the interview. 
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ALTERNATIVES 
Taking part in this research study is voluntary. Instead of being in this research study, you have 
the following option: 
• Decide not to participate in this research study 
CONFIDENTIALITY 
Your confidentiality is very important to us.  Potentially identifiable information about you will 
consist of audio recordings and transcriptions of interviews. Data is being collected for research 
purposes only.  Your data will be identified by ID numbers, not names, and stored separately 
from medical records in a locked research area. All study related documents and audio tapes will 
be stored in a secure location until the study has ended and all data analyses is complete.  At that 
time, all study material will be placed in a secured long term storage facility until it is deemed 
appropriate to destroy the study material. 
The results of this research study may be presented at meetings or published, but your name will 
not ever be used in these presentations or papers. 
We will not tell anyone the answers you give us; however, the consent form signed by you may 
be looked at or copied for research or legal purposes by the sponsor of the research, or by 
Virginia Commonwealth University.   
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
You do not have to participate in this study. If you choose to participate, you may stop at any 
time without any penalty. You may also choose not to answer particular questions that are asked 
in the study. 
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Your participation in this study may be stopped at any time by the study staff without your 
consent. The reasons might include: 
 the study staff thinks it necessary for your health or safety; 
 you have not followed study instructions; 
 the sponsor has stopped the study; or 
 administrative reasons require your withdrawal. 
If you are removed from the research study, the research Investigator will explain to you why 
you were removed 
QUESTIONS 
If you have any questions, complaints, or concerns about your participation in this research, 
contact: 
Omar El Shahawy, MBBCh, MPH (804) 628-2997 or  
Jennifer Elston Lafata, PhD (804) 628-3293 
The researcher and study staff named above are the best persons to call for questions about your 
participation in this study.  
If you have any general questions about your rights as a participant in this or any other research, 
you may contact: 
 Office of Research 
 Virginia Commonwealth University 
 800 East Leigh Street, Suite 3000 
 P.O. Box 980568 
 Richmond, VA  23298 
 Telephone: (804) 827-2157 
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Contact this number for general questions, concerns or complaints about research. You may also 
call this number if you cannot reach the research team or if you wish to talk with someone else.  
General information about participation in research studies can also be found at 
http://www.research.vcu.edu/irb/volunteers.htm. 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says that 
I am willing to participate in this study.  I will receive a copy of the consent form once I have 
agreed to participate. 
 Participant name printed   Participant signature  Date 
________________________________________________ 
Name of Person Conducting Informed Consent  
Discussion / Witness   
(Printed) 
________________________________________________ ________________ 
Signature of Person Conducting Informed Consent   Date 
Discussion / Witness  
________________________________________________ ________________ 
Principal Investigator Signature (if different from above)   Date 
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Correct marking=              Incorrect marking =  
Appendix 3: Survey Instrument 
A National Survey of Primary Care                  
Physicians in the United States 
About E-cigarettes  
 
 
 
 
 
 
Instructions 
 
 We would like to know your opinions and ideas about e-cigarettes. Please answer each 
of the following questions whether or not you have previously discussed or 
recommended e-cigarettes to your adult patients.  
 
 There are no right or wrong answers, we want to know your personal opinion as a 
practicing physician. 
 
 Questions in this survey pertain to your adult patients who smoke any type of 
tobacco. The survey takes approximately 15-20 minutes to complete. Upon return of 
your completed survey, you will receive a $10 gift card of your choice as a small “thank 
you” for your help with the study. 
 
 You may use a pen or pencil to complete this survey. 
 
 Please mark your answers as follows: 
 
 
 
 Unless instructed otherwise, mark only one answer per item. 
 
 Some questions may seem similar, but please answer each question. 
 
 Your answers are strictly confidential; please do not put your name on the survey. 
 
Thank you very much for taking the time to complete this survey! 
Please return the completed survey in the enclosed stamped 
envelope. 
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Section One: E-cigarette Discussions and Experiences 
 
1. Have you ever discussed e-cigarettes with your adult patients who smoke? 
  No     Go to question #2  
  Yes   How often have you 
discussed e-cigarettes with your 
patients? 
 When you discuss e-cigarettes with your patients, who 
        usually raises the topic? 
       Rarely       I usually raise the topic 
      Sometimes       My patients usually raise the topic 
      Often       It is equally as likely that I or my patients raise the topic 
      Almost always  
 
2. Over the PAST three months, how often have you recommended e-cigarettes to any of your adult 
patients who smoke? 
 
Never Rarely Sometimes Often 
Almost 
Always 
For smoking cessation     
For harm reduction     
 
 
3. We are interested in knowing your thoughts about the impact of recommending e-cigarettes to adult 
patients who smoke. In general, do you think your recommending e-cigarettes to patients is ….. 
 
Harmful 
   
Neither 
   
Beneficial 
 
Valuable 
   
Neither 
   
Worthless 
 
Bad Practice 
   
Neither 
   
Good practice 
 
Pleasant 
   
Neither 
   
Unpleasant 
 
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4. How likely is it that your patients’ use of e-cigarettes would result in each of the following? 
                                                     Very 
                                                          Unlikely 
Neither Likely 
Nor Unlikely  
  Very 
  Likely 
Sustain their nicotine dependence       
Help them to quit smoking       
Limit secondhand smoke exposure to their 
    families and friends       
Decrease their cancer risk       
Make patients less likely to use 
    conventional cessation medications       
5. Please indicate your level of agreement with each of the following statements. 
 
                                                                     Strongly 
                                                                      Disagree 
    Neither Disagree 
      Nor Agree  
Strongly 
Agree 
I feel under pressure to recommend 
    e-cigarettes to my patients       
Screening for e-cigarette use is as important 
    as screening for traditional cigarette use       
E-cigarette use can create dual tobacco users       
I am concerned about future litigation 
    if/when I recommend e-cigarettes       
Most people who are professionally 
    important to me recommend e-cigarettes       
 
6. Over the NEXT three months, how likely are you to recommend e-cigarettes to each of the following 
types of patients? 
      Not at All
                                                                            Likely  Neither 
                 Very  
Likely
Heavy smokers refusing to quit       
Light smokers wanting to quit        
Former smokers with a recent relapse       
Smokers with prior unsuccessful quit 
    attempts       
Smokers with COPD       
Heavy smokers wanting to quit       
Light smokers refusing to quit        
Smokers with a previously diagnosed 
    mental illness       
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Section Two: E-cigarettes perceptions 
7. Please indicate the extent to which each of the following groups disapprove or approve of your 
recommending 
e-cigarettes to your patients who smoke. 
                                                          Disapprove Neither Approve
Specialty physicians to whom I refer 
    my patients       
The professional societies to which I 
    belong       
My primary care physician colleagues       
My patients who smoke       
Most people whose opinion I value in 
    my profession       
8. Please indicate the extent to which you agree or disagree with each to the following statements. 
                                                        Strongly 
                                                        Disagree 
Neither Agree 
Nor Disagree 
Strongly
Agree
Whether I recommend e-cigarettes to 
    my patients, is entirely up to me       
I am confident I could  recommend  
    e-cigarettes if I wanted to       
Recommending e-cigarettes to my 
    patients is easy to do       
I am confident in my ability to counsel 
    patients about e-cigarettes use       
I am confident in my ability to counsel 
   patients about tobacco use in general       
 
 
9. How much does each of the following factors affect the difficulty/ease of you recommending e-
cigarettes to your patients who smoke? 
  Makes it
Very
  Difficult
 Neutral 
Makes it
Very
Easy
The current safety standards for 
    e-cigarettes       
Patients’ interest in trying e-cigarettes        
Currently available information on 
    e-cigarettes       
Time available for tobacco use 
    counseling during office visits       
My current knowledge of e-cigarettes        
 
 
You are now done with two sections! Please keep going. 
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Section Three: E-cigarettes in relation to tobacco products and tobacco 
dependence treatment 
10. How harmful are the following tobacco products to the health of your patients? 
 
Not at All
  Harmful
 
Moderately 
Harmful 
Extremely
Harmful
Traditional cigarettes       
Tobacco Pipes       
Waterpipes (Hookah or Narghile)       
E-cigarettes       
Cigars, Cigarillos and Little cigars       
Smokeless tobacco       
 
11. We are interested in your knowledge of e-cigarettes. Please 
indicate whether each of the following statements are true or 
false 
True False 
I Don’t 
Know 
E-cigarettes are currently regulated by the FDA   
Some e-cigarettes can deliver more nicotine than traditional cigarettes   
The nicotine liquid used in e-cigarettes contains carcinogens   
E-cigarettes do not diminish lung function   
Some e-cigarette brands do not deliver nicotine   
 
Thanks, you are almost done with section three! 
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12. What is your level of agreement with each of the following statements? 
 
 
 Strongly 
 Disagree
Neither Agree 
or Disagree
Strongly
Agree
E-cigarettes are a gateway to smoking  among 
    non-smokers       
My patients’ interest in e-cigarettes is/would be 
    the primary reason for my recommending them       
More FDA regulations for e-cigarettes would 
    encourage me to recommend them        
 
13.  The following questions are about you. Yes No 
Have you ever tried traditional cigarettes?  
Have you ever tried e-cigarettes?  
 
16.    Have you used any tobacco product within the last 30 days? (check all that apply) 
 Yes, traditional cigarettes  
 Yes, e-cigarettes  
 Yes, other tobacco products  
 No, but I used to smoke in the past  
 No, and I have never smoked on a regular basis 
 
 
17. In general, how much would you trust information about medical topics from each of the following sources?  
Not at 
All A Little Some A Lot 
Peer-reviewed research studies    
FDA publications/recommendations    
Professional conferences/scientific meetings    
Patients’ experiences    
The lay press    
CDC publications/recommendations    
US Preventive Services Task Force 
publications/recommendations    
Your physician colleagues    
Newsletters or other information sent to you from medical 
societies to which you belong    
Thanks, you are almost done, only two pages left! 
 
 
95 
 
 
The Next questions are about the patients you deliver care to and how you spend your time in a 
typical week. 
 
 
 
18. During a typical week, approximately how many adult patients do you see?    ____________ 
 
19. What is the size of your practice?  
 
Solo 
practice 
Partner 
practice 
3 - 5  6 - 10  11 or more 
 
20. Which answer represents the most approximate percentage for each of the following?  
 
None 
 
Less than 
25% 
 
25-49% 
 
50-75% 
 
More 
than 75% 
 
How many of the patients you see in a typical week do you consider 
    to be your regular patients?     
During a typical week, approximately how much of your professional 
    time do you spend providing primary care to adult patients?     
 
 
More about You 
21. Have you ever received formal training in smoking cessation counseling? 
 Yes 
 No 
22. Do you have an affiliation with a medical school, such as an adjunct, clinical, or other faculty 
appointment? 
 Yes 
 No 
23. What is your gender? 
 Male 
 Female 
24. What is the year of your birth?         19 ________            
25. What is your ethnicity? 
 Hispanic or Latino 
 Not Hispanic or Latino 
 
 
 
 
Write a number in this box
Write in this box
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26. What is your race? (Check all that apply) 
 
  White  
  Black/African American  
 Asian  
 Native Hawaiian/other Pacific Islander      
 American Indian/Alaska native  
27. In what year did you start practicing medicine, after completing residency or fellowship?  
 
 
___________ 
 
 
Your Gift Card Selection 
28. What kind of gift card would you like? 
 Amazon 
 Target 
 
Thank you very much for completing the survey. 
 
Please return the completed survey in the enclosed stamped 
envelope. 
 
or mail it to:  
 
Omar El-Shahawy 
830 East Main street (9th floor) 
Social and Behavioral Health Department 
School of Medicine 
Virginia Commonwealth University 
PO Box 980149 
Richmond, VA, 23298 
 
  
Write in this box 
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